Roadmaps to regulation : MDMA by Moore, K et al.
Roa d m a p s  to  r e g ula tion  : MDMA
Moo r e,  K, Wells, H  a n d  Feilding,  A
Tit l e Roa d m a p s  to  r e g ula tion  : MDMA
Aut h or s Moor e,  K, Wells, H  a n d  Feilding,  A
Typ e Mo nog r a p h
U RL This  ve r sion  is available  a t :  
h t t p://usir.s alfor d. ac.uk/id/e p rin t/56 0 2 7/
P u bl i s h e d  D a t e 2 0 1 9
U SIR is a  digi t al collec tion  of t h e  r e s e a r c h  ou t p u t  of t h e  U nive r si ty of S alford.  
Whe r e  copyrigh t  p e r mi t s,  full t ex t  m a t e ri al  h eld  in t h e  r e posi to ry is m a d e  
fre ely availabl e  online  a n d  c a n  b e  r e a d ,  dow nloa d e d  a n d  copied  for  no n-
co m m e rcial p riva t e  s t u dy o r  r e s e a r c h  p u r pos e s .  Ple a s e  c h e ck  t h e  m a n u sc rip t  
for  a ny fu r t h e r  copyrig h t  r e s t ric tions.
For  m o r e  info r m a tion,  including  ou r  policy a n d  s u b mission  p roc e d u r e ,  ple a s e
con t ac t  t h e  Re posi to ry Tea m  a t :  u si r@s alford. ac.uk .
1 
ROADMAPS TO REGULATION
MDMA
  
 
Roadmaps to Regulation: MDMA

  
 
Roadmaps to Regulation: MDMA
Authors
Karenza Moore, Hattie Wells, Amanda Feilding
Convenor
Amanda Feilding
Testimonials by
Anne-Marie Cockburn, Neil Woods and Ben Sessa
BECKLEY FOUNDATION PRESS
We gratefully acknowledge the generous support of our funders for this project. 
Our sincere thanks to the John Paul Getty Jr. Foundation, who were the main 
funders for this series of reports Roadmaps to Regulation, which include: 
Cannabis, Psychedelics, MDMA, and New Psychoactive Substances. The 
series was convened by Amanda Feilding, as part of the Beckley Foundation’s 
Global Initiative for Drug Policy Reform. 
We would also like to give special thanks to the Open Society Foundations (OSF), 
Tides Foundation and the Flora Family Foundation for their supplementary 
financial support towards these publications.
Roadmaps to Regulation: MDMA
First published by the Beckley Foundation Press 2019
ISBN: 978-1-907072-04-8
Text Copyright © The Beckley Foundation 2019
All rights reserved. No part of this publication may be reproduced in any form 
or by any means without the written permission of the publisher.
Beckley Foundation Press
Beckley Park, Oxford, 
OX3 9SY – United Kingdom
www.beckleyfoundation.org
Cover image: Sasha Frost (Front) , Hypnotoad (Back)

 
 
Table of contents
Preface, by Prof David Nutt
Executive Summary
Introduction
Chapter One: MDMA Past and Present
The History of MDMA: A theraputic and recreational drug
UK MDMA use and consumption practices today
Global MDMA use
Chapter Two: MDMA-Related Harms Under Prohibition
Inherent harms? ‘High-dose’ and adulterated MDMA products
Harms associated with use
Acute harms and unwanted effects
Sub-acute effects and chronic harms
Generations lost: The harm of inaction
Harms associated with production
Harms associated with the product
Harms associated with distribution (supply)
Financial costs of retaining the prohibition status quo
Lost benefits
Recreational use 
Clinical and therapeutic use
Harm reduction under prohibition
 
 
1 . 1
1 . 2
1 . 3
2 . 1
2 . 2
2 . 2 . 1
2 . 2 . 2
2 . 3
2 . 4
2 . 5
2 . 6
2 . 7
2 . 8
2 . 8 . 1
2 . 8 . 2
2 . 9
 
 
ii
9
26
32
32
40
44
46
46
53
53
55
60
63
64
68
73
74
74
74
78
Chapter Three: Developing a Roadmap to Regulation: MDMA
The goals of policy reform
Proposed model for reform
Phase 1 
Rescheduling MDMA
Decriminalising possession of MDMA for personal use
Phase 2: Building a strict state-regulated legal market for MDMA
Regulating production
Regulating distribution (supply)
MDMA product outlets: Licensed vendors (pharmacy model)
User controls and harm reduction
Pricing and purchase limits
Marketing controls and information campaigns
MDMA use in the night-time economy: MDMA-friendly spaces
On-site MDMA sales in the night-time economy
Monitoring and evaluation
Conclusion
Testimonials
Why MDMA should be regulated, by Anne-Marie Cockburn 
(Martha's mum)
On the front line of the War on Drugs, by Neil Woods
MDMA-assisted psychotherapy as a potential treatment for 
alcoholism, by Dr Ben Sessa 
References
3 . 1
3 . 2
3 . 3
3 . 3 . 1
3 . 3 . 2
3 . 4
3 . 4 . 1
3 . 4 . 2
3 . 4 . 2 . 1
3 . 4 . 3
3 . 4 . 3 . 1
3 . 4 . 3 . 2
3 . 4 . 3 . 3
3 . 4 . 3 . 4
3 . 4 . 4
84
84
85
86
86
89
93
97
99
99
103
103
104
106
110
111
112
116
116 
119
122 
126

I am delighted to be asked to provide a preface to this important policy document 
as MDMA has been concern of mine since the early 1990s when I was first asked 
to help advise the UK government on how to mitigate its harms. At the time I 
had recently returned from the USA and still cherished the belief that UK drugs 
policy was more evidence-based than that in the USA. Initially the discussions 
about MDMA were sensible, with our policy recommendations of education, 
and chill out rooms plus free water in clubs being instigated – and effective. 
However a few years later when I accepted to take on the chair of the 
scientific committee of the ACMD I found that things had deteriorated. When 
I tried to instigate a sensible discussion about whether the harms of MDMA 
really warranted Class A, Schedule 1, status I was confronted with statements 
such as “I would never support a downgrade of MDMA classification” “it would 
give the wrong message”. Still I persevered and instigated a new structured harms 
assessment process that clearly showed MDMA was more like amfetamine 
sulphate [Class B] than crack cocaine [Class A] in terms of harms. But the 
Home Office were resistant and refused to allow the ACMD to do a formal 
review of MDMA. 
Eventually a few years years later, after being admonished by the 
parliamentary Science and Technology committee, the Home Office allowed 
us to review MDMA, though at the hearing the Drug Minister made it very 
clear that they would not downgrade MDMA whatever findings our review 
came up with. 
To help make politicians and the public make sense of this impasse I wrote 
a thought piece – that was to become my most cited paper with over 7000 
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downloads. The paper was entitled Equasy – a harmful addiction with implications 
for the current debate on drug harms. In it I compared the harms of ecstasy 
[MDMA] with those of another addiction I called equasy [equine addiction 
syndrome]. The latter idea had come to me as a result of seeing a patient who had 
suffered significant brain damage from falling from a horse and was developed 
when speaking about comparative harms of different activities at a Beckley 
Foundation event at the House of Lord’s the year before. As most of you will 
know I concluded that MDMA was less harmful than horse riding especially 
when the latter involves jumping and eventing.
I hoped that this comparative analysis would help politicians become more 
reasonable about MDMA but the opposite happened. The Home Secretary 
at the time was Jacqui Smith who reacted very aggressively, calling me up and 
shouting down the phone that I had exceeded my position as ACMD Chair 
by comparing a legal activity with an illegal one. I tried to explain that we had 
to have some harmful activities with which to compare the harms of drugs 
in order to decide if a drug was harmful enough to be banned; but she just 
couldn’t [or wouldn’t] get it. She showed the same level of intransigence when 
the ACMD report came out recommending downgrading MDMA to Class 
B and this suggestion was summarily dismissed. So MDMA stayed as a Class 
A drug, and the effective ban on research that its Scheduling in the 1980s had 
resulted in, persisted. 
But there is now light at the end of the tunnel. Research on the brain 
mechanisms of MDMA conducted by our group funded by Channel 4 opened 
up people’s eyes to the science of MDMA and the pioneering work by MAPS 
demonstrating its utility in treatment-resistant PTSD has helped to change 
public attitudes. Also the hostile pseudo-scientific claims that MDMA use 
damaged the brain have been overturned by more recent better controlled 
scientific analyses. Now I give a lecture on MDMA with the title “A decade of 
MDMA – from brain damage to brain healing” which emphasises the complete 
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volte face that has occurred as a result of many research teams around the world. 
In this report you will discover the most recent one by Ben Sessa and others 
in our Unit showing how two MDMA treatments given as part of an alcohol 
treatment programme can help people with PTSD overcome their alcohol 
dependence. I believe that this is just the start of a major breakthrough in the 
use of MDMA therapy that will occur if it gets re-scheduled as per this report. 
Thanks must go to the Beckley Foundation for leading this vital campaign.
Prof David Nutt DM FRCP FRCPsych FMedSci DLaws 
Former of the Advisory Council of Misuse of Drugs
Edmond J. Safra Prof of Neuropsychopharmacology 
Imperial College London 
November 2019
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Executive Summary
MDMA is well established as a popular psychoactive substance across much of 
the Western world. Hundreds of thousands of people break the law to access its 
effects, which include increased energy, euphoria, and enhanced sociability. The 
categorisation of MDMA as a Class A drug in the UK and Schedule 1 drug 
internationally – categories reserved for drugs deemed to pose the highest risk 
to individuals and society – has never meaningfully disrupted its supply, nor its 
widespread use. MDMA is cheaper and purer than ever before and is available 
at the click of a mouse via darknet drug markets. 
For several years, MDMA-related adverse events and fatalities have been 
increasing in the UK, with some claiming that taking MDMA today is the 
riskiest it has ever been. Responses are polarised between those who assert 
that the risks of MDMA use necessitate mitigation through prohibition and 
increased law enforcement, and those who perceive prohibition to be exacerbating 
these risks by exposing users to an unregulated market of pills and powder of 
unknown strength and quality. Whichever view you take, current policy is not 
meeting its goal of reducing harms, and greater control of MDMA production, 
distribution, purchase, and consumption is needed in order to prevent MDMA-
related emergencies.
This report examines the acute, sub-acute, and chronic harms related to 
MDMA use in detail. We examine the production, distribution, purchase, and 
consumption of the drug; related risks and harms; and the impact prohibition 
has on these, as well as the potential impact of alternative policies. Crucially, 
our evidence shows that many harms associated with MDMA use arise 
from its unregulated status as an illegal drug, and that any risks inherent to 
MDMA could be more effectively mitigated within a legally regulated market. 
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Under prohibition, people purchase MDMA pills, crystal, and powder 
from an illegal market, with little certainty as to what these products contain. 
Given that illegal drugs are not subject to strict production standards, 
consumers are exposed to the risks of poisoning or accidental overdose as a 
result of contamination, adulteration, and unknown strength and purity. Naïve 
commentators demonise the drug and simply urge young people to ‘just say no’, 
whilst failing to account for those who say ‘yes’. In the meantime, preventable 
deaths continue to occur, and otherwise law-abiding people are punished 
for non-violent offences such as the possession or social supply of MDMA. 
Governments and the mainstream media persist in perpetuating the myth that 
the War on Drugs is winnable if it were fought harder, and those calling for 
drug policy reform – as we do here – are framed as ‘radicals’ who have little or 
no regard for the health and wellbeing of citizens. 
This characterisation could not be further from the truth. Those calling for 
careful reform to existing drug policy include the parents of young people whose 
lives have been lost or ruined by harms related to the prohibition of MDMA. We 
incorporate their voices in this report alongside those of academics and former 
police officers, highlighting the ‘broad church’ of those dedicated to fighting for 
reform. This includes scientists undertaking ground-breaking research into the 
therapeutic potential of MDMA, who work within a regulatory regime that 
makes such research exorbitantly expensive and time-consuming, because of 
the Schedule 1 status that MDMA holds in the UK.
As we enter the fourth decade of MDMA’s widespread use, new thinking 
is needed on how to better control production and distribution, and on how 
to reduce the risks associated with its consumption. There is growing evidence 
to support reorienting drug policy away from an ideologically driven criminal 
justice-led model to one rooted in pragmatic health and harm reduction 
principles. This is reflected in the widespread reform of cannabis laws occurring 
in numerous jurisdictions around the world, and the growth of treatment 
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programmes for heroin users which include prescription heroin and supervised 
injecting rooms. These hard-fought policy changes acknowledge the failure of 
prohibition to meet its goals and produce a ‘drug-free world’. They are built on 
a robust and ever-growing evidence base which demonstrates how permitting 
or prescribing the use of legally regulated drugs improves health and safety 
outcomes for people who use drugs and their communities at a reduced cost to 
the state, whilst also providing wider employment and economic opportunities. 
This logic can be extended to the use of MDMA and other currently prohibited 
psychoactive substances.
Roadmaps to Regulation: MDMA follows this pragmatic path and pursues 
policy aims which many of us share, such as improvements in public health 
promotion, targeted harm reduction, evidence-informed policy and practice, 
human rights, social justice, participatory democracy, and effective governmental 
expenditure. For the first time, we outline detailed recommendations for drug 
policy reform to better control the production, distribution, purchase, and 
consumption of MDMA products. Reform and the reduction in MDMA-
related harms this will bring cannot happen overnight. The changes we outline 
here, which culminate in a strictly regulated legal market for MDMA, are to be 
phased in gradually and closely evaluated through independent policy research 
to ensure health and social outcomes are properly documented, with findings 
folded back into the ongoing reform process. 
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Key findings supporting our recommendations
Harms associated with MDMA under prohibition
 • As with all drugs, certain adverse effects can be caused by or associated with 
MDMA use. The most serious of these include hyperthermia, hyponatraemia 
(abnormal water regulation which causes swelling in the brain), serotonin 
syndrome, and isolated physiological disorders such as cardiac events and liver 
failure, all of which may result in death. These adverse effects occur through 
various mechanisms, none of which is as simple as an ‘overdose’. Whilst it 
is widely accepted that risks are increased with higher doses of MDMA, 
there is no established consensus on the fatal blood concentration level of 
MDMA, and it is often unclear to what extent the harms are attributable 
to the toxicity of MDMA alone, or to the circumstances in which it is taken.
 
 • Hyperthermia is the most commonly reported life-threatening medical 
complication associated with MDMA use. The risk for users is exacerbated by 
external factors. These include dancing for prolonged periods in overcrowded 
venues with high ambient temperatures and insufficient ventilation, although 
risks may not be confined to dance settings. MDMA increases metabolic 
heat generation and impairs heat dissipation through vasoconstriction, 
which typically increases body temperature in a manner comparable to 
moderate exercise. When paired with other heat-generating activities, severe 
problems can arise for a small but significant number of people. 
 • Hyponatraemia, another MDMA-related medical complication that has 
resulted in fatalities, is caused by excessive water intake, often ingested 
in order to prevent dehydration and overheating following MDMA 
consumption. MDMA causes the brain to release certain chemicals (e.g., 
arginine vasopressin) that tell the body to retain water, which is problematic 
if an excess of water is subsequently consumed. 
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 • Both hyperthermia and hyponatraemia could be prevented with 
comprehensive harm reduction advice and services. Neither adverse effect 
has ever occurred in a clinical setting. 
 • Unlike other recreational legal and illegal drugs such as cannabis and alcohol, 
occasional use of MDMA is typical. Prolonged daily use – an indicator of 
problematic use – is atypical and usually only associated with co-occurring 
mental or physical conditions. Given this, harms associated with chronic 
use of MDMA may only be relevant for a minority of MDMA users.
 • It remains difficult to define conclusively the risks associated with long-term 
regular use of MDMA, due to multiple confounding factors (e.g., polydrug 
use, including mixing MDMA with alcohol; purity of MDMA products; 
and use setting) and the fact that the only available evidence comes from 
animal experiments, observational studies of human users, and accounts of 
harm such as clinical case reports. Of these, only the animal experiments 
have gathered data on the effects of the use of pure MDMA.
 • However, proposed neuropsychological risks include neurological and 
cognitive impairment, psychological and mood problems, and sleep 
disturbances, which some claim are the result of direct neurotoxicity. The 
neurotoxicity of MDMA continues to be strongly debated but there is 
evidence to suggest that heavy use of MDMA may contribute to temporary 
impairments in neuropsychological functions. Liver toxicity has also been 
reported, although it is impossible to ascertain whether this was driven 
primarily by MDMA, or was the result of polydrug use or of an adulterated 
product. 
 • The number of MDMA-related deaths has been rising in the UK since 2010. 
This has been mirrored by an increase in ‘high-dose’ MDMA/‘Ecstasy’ pills and 
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powders in circulation, and the presence of high-risk adulterants such as PMA 
(paramethoxyamphetamine) and PMMA (paramethoxymethamphetamine) 
in pills sold as MDMA. Recent drug-testing results by the harm reduction 
organisation The Loop (UK) have identified pills containing as much as 300 
mg of MDMA, which is considerably more potent than in previous years. 
Although the relationship between dose and adverse effects is complicated 
and cannot be divorced from the user and the user’s setting, a significant 
proportion of MDMA-related medical emergencies and deaths are cases of 
accidental poisoning through unintentional excessive doses and adulteration 
with, or substitution of, other substances.
 • Assessing the risk profile of MDMA requires distinguishing between 
MDMA of clinical purity and MDMA produced and sold illegally. It also 
requires identifying the risks specifically related to the context in which 
the drug is consumed. Recreational MDMA use has only been studied 
under conditions of prohibition, and so the evidence can only tell us, at 
best, how risky MDMA may be in that specific context. Aside from the 
pre-prohibition era of MDMA use, recreational users have not had access 
to a pure standardised MDMA product, so we cannot know for certain 
what harms, at what levels, would be attendant to that scenario. We know 
that clinical-grade MDMA can be administered with a high degree of 
safety in a controlled therapeutic setting if sufficient measures are taken to 
reduce risks: over 1,500 people have participated in studies investigating the 
effects and therapeutic use of MDMA with no unexpected serious adverse 
events requiring emergency treatment reported. Although recreational 
use is distinct from therapeutic use, clinical research helps us to better 
understand any risks associated with pure MDMA and how these risks 
can be managed. 
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How prohibition exacerbates these risks
 • Currently in the unregulated criminal market, MDMA potency and purity is 
highly variable: pills have been found containing less than 20 mg of MDMA 
while others contain more than 300 mg of MDMA. MDMA may also 
contain adulterants that are psychoactive and/or toxic. As users are unaware 
of the content of their pills, they may be vulnerable to overdosing or other 
problems caused by product adulteration, particularly if they choose to 
consume multiple pills. The lack of consistency makes it difficult to establish 
stable social norms, moderate use, and harm reduction measures, although 
over the last 30 years of rave and dance culture, specific grassroots risk 
mitigation measures – such as breaking pills into quarters – have emerged. 
Ultimately people who take MDMA want to stay safe.
 • The variability in MDMA potency and purity is a direct result of global 
and national prohibitionist policies. Recent developments around in situ 
drug safety testing are an attempt to mitigate the risks of such variability. 
These risks, such as overdose and/or poisoning, are by no means inevitable 
or inherent to the drug. If MDMA were clinically produced and legally 
distributed, users would be assured of the product content and appropriate 
dosage, and be able to make more informed decisions regarding their 
MDMA use. In this way the principal risks we associate with MDMA use 
would be greatly reduced. 
 • Prohibition makes users less likely to seek medical assistance for fear of ‘getting 
into trouble’ with the authorities, especially amongst members of marginalised 
communities who already receive disproportionate law enforcement attention 
relative to their involvement in drug markets. Young people may be reluctant 
to contact emergency services if they, or a friend, experience an adverse 
reaction to a substance, out of fear of (legal) repercussions in relation to 
social dealing and/or potential media coverage of their role in the incident. 
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 • Pressures on MDMA users to avoid detection, and on nightclubs, warehouse 
parties, and festivals to demonstrate zero-tolerance, create conditions that are 
not conducive to responsible use. Intensive searches and drug (sniffer) dogs 
may unintentionally encourage users to take all their drugs at once before 
entering party venues. This has led to several young people experiencing 
adverse effects as a result of not wanting to be caught with their drugs ‘on 
the door’ of nightclubs or events. Avoiding such detection can also lead 
people to purchase their drugs from unknown dealers inside the venue 
who, in comparison to dealers known by the user, may offer an even more 
unpredictable product. The ‘zero-tolerance’ approach of certain venues or 
events can lead people to consume MDMA in less regulated private parties 
or unlicensed venues, where an MDMA-related emergency may take longer 
to receive medical attention.
 • Adolescents and those with pre-existing genetic vulnerabilities, or with 
specific health diagnoses that may be contraindicated for MDMA use 
(such as heart conditions or impaired liver function) are not protected by 
prohibition. There are no age restrictions in a criminal market, no education 
at point of sale on the risks associated with various products, and no purchase 
limits to curb heavy use or ‘bingeing’. 
 • The development of online drug sales via darknet markets and social media 
dealing poses specific kinds of risks and opportunities in addition to the 
more familiar practice of purchasing drugs from criminal markets. The 
internet has created an easily accessible supply route for ‘tech-savvy’ young 
people who may not otherwise have had access to street or social dealers; 
this may increase MDMA availability for certain populations. However, for 
some people, online modes of purchase may be preferable given that they 
avoid the need to meet dealers in person, and there is some degree of quality 
control through user ranking/reports on vendors.
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 • Harm reduction is restricted within a prohibitionist policy regime because 
the dominant focus is on drug prevention and abstinence rather than safer 
use. Risks such as hyperthermia and hyponatraemia are exacerbated by 
certain contexts of use and environmental factors. Under prohibition, venues 
and events are supposed to operate with a ‘zero-tolerance’ approach to drug 
taking. For the most part, they are under no obligation to provide basic harm 
reduction measures, such as visible free drinking-water supplies and adequate 
ventilation and temperature control, let alone measures such as in-house 
medics and pill checking that could further prevent adverse effects. Indeed, 
venues and events may be stigmatised for taking a more ‘tolerant approach’ 
should an MDMA-related emergency occur.
 • The opportunity for education at point of sale, or information campaigns 
to raise awareness of the risks associated with MDMA use for certain 
populations and the relative risks of different dosages and contexts of use, is 
lost within an illegal market. Likewise, the lack of regulations for MDMA 
producers and distributors means they may remain largely ignorant of the 
harms to health posed by certain production techniques or the presence of 
certain contaminants in the products they make and sell.
Harms introduced by prohibition
 • Prohibition has created a lucrative illegal MDMA market that generates 
wealth for entrenched criminal organisations and criminal entrepreneurs. 
Those involved in large-scale production, importation, or distribution of 
MDMA and other illegal drugs are likely to engage in other criminal 
behaviour as part of their business practice, for example, violence towards 
consumers and rivals, money laundering, and corruption.
 • There is no evidence to suggest that criminalising people who use drugs 
meaningfully disrupts the supply of controlled drugs or reduces their 
18
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availability. However, criminalising (often young) MDMA users can have 
a devastating impact on their lives, resulting in the loss of education or 
employment opportunities; negatively impacting housing, personal finance, 
and social relationships; and, ironically, potentially increasing the likelihood 
of them developing more problematic drug-using behaviour, especially if 
they spend time in prison. 
 • Many people who use MDMA report obtaining their drugs from friends
and established contacts. This creates a risk of criminalisation for young
people engaging in non-profit ‘social supply’ amongst peer groups, or small-
scale opportunistic dealing. Drug dealing can also attract young people in
situations of social vulnerability, which can further perpetuate cycles of harm, 
trauma, and exclusion if they are prosecuted. The harms of criminalisation
are arguably greater than the harms caused by occasional use of MDMA.
 • The development of markets for novel psychoactive substances (NPS)
intended to mimic the effects of MDMA is directly related to the drug’s
illegal status. Illegal production results in a market affected by inconsistent
quantity and quality of production. If MDMA supplies run scarce due to
law enforcement measures or the quality diminishes due to production
difficulties, alternatives are sought. A decade ago, NPS as legal replacements
for MDMA swiftly emerged, with some MDMA users simply adding them
to their polydrug repertoires. NPS such as mephedrone, a stimulant which
enjoyed immense if short-lived popularity in the UK, turned out to have
a higher risk profile than MDMA, was banned in 2010, and now plagues
marginalised stimulant users. NPS are the genie that prohibition let out of
the bottle.
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Benefits lost through prohibition
 • Before the use of MDMA was prohibited, it was employed by psychotherapists
as a valuable and effective tool to augment the psychotherapeutic process,
particularly for overcoming fear and anxiety associated with trauma, and
in the context of couples’ therapy. Due to the regulatory hurdles imposed
by the prohibition of MDMA, research into this particular use of MDMA
was seriously impeded for almost twenty years. Only recently has it been
revived, largely due to the efforts of the Multidisciplinary Association for
Psychedelic Studies. Phase 1 and Phase 2 clinical trials of the use of MDMA
in the treatment of post-traumatic stress disorder have been completed
with positive results, and Phase 3 trials are now underway following the US
Food and Drug Administration approval and designation of MDMA as a
‘breakthrough therapy’ for post-traumatic stress disorder.
 • Other research is being conducted to see whether MDMA-assisted
psychotherapy can help autistic adults with social anxiety, patients with
anxiety relating to a life-threatening illness, and people with alcoholism.
Prohibition imposes considerable financial and bureaucratic obstacles to
preclinical and clinical research involving prohibited drugs, resulting in
trials taking longer and costing more – as much as ten times the equivalent
research with unprohibited drugs such as alcohol. A gram of clinically made
MDMA can cost researchers in the UK £10,000 as compared to its average
street price of £30–£40 per gram.
20
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Conclusions
Global and UK drug policy is not meeting its stated goals of reducing the 
demand for MDMA and restricting the supply. The use of MDMA has remained 
relatively consistent amongst adults over the last thirty years, and the supply 
has only experienced periods of minor disruption, during which lesser-known 
NPS entered the market as (often more dangerous) substitutes. Prohibition 
needlessly exacerbates the risks of medical emergencies and death amongst 
people who use MDMA. An illegal market leads to the sale of MDMA products 
of variable potency and purity. Contaminated and adulterated products can 
cause poisoning, and a lack of awareness regarding purity and dose can lead to 
accidental overdoses, one of the more common causes of drug-related fatalities. 
Criminalising users hinders the dissemination of important information and 
advice about safer forms of use, not to mention the devastating impact a custodial 
sentence and criminal record can have on a person’s life. Finally, in prohibiting 
MDMA use, governments have failed to capitalise on the therapeutic benefits 
it could offer users and society. The rescheduling of MDMA would facilitate 
further medical research and the development of much needed new treatments 
for a range of health conditions.
21
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Recommendations for initial reforms
Moving to a strictly regulated commercial market may take time as political, 
legal, and practical hurdles need to be overcome. Thus, we propose the following 
interim measures to reduce some of the harms associated with the current system:
 • Reschedule MDMA from a Schedule 1 to Schedule 2 drug under the Misuse
of Drugs Regulations in the UK, and equivalent legislation internationally.
This will reduce the political, bureaucratic, and cost barriers to scientific
research associated with the Schedule 1 status and facilitate further research
into MDMA’s therapeutic uses, as well as allowing us to improve our
understanding of its physiological effects.
 • Decriminalise the possession of MDMA and all drugs to remove the
devastating social and economic effects of being criminalised for drug
possession or limited social supply. As well as improving social justice
outcomes for users of MDMA (a principal aim of any drug policy),
decriminalisation will improve health outcomes by removing barriers to
harm reduction and health services, and increasing willingness to access
them amongst vulnerable populations who might have previously feared
legal repercussions. To reap the full benefits that could be derived from
decriminalisation and to help tackle the disproportionality and racial
bias of drug policing, it is appropriate that criminal penalties be removed
for the possession of any drug (and not solely MDMA), as is the case
in Portugal.
 • Through decriminalisation, enable the comprehensive rolling-out of drug
safety checking and other successful harm reduction interventions to occur, 
which would go some way towards reducing the harms associated with
unregulated MDMA products.
22
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• Licences would be awarded to selected pharmaceutical manufacturers to 
produce MDMA certified by Good Manufacturing Practices (GMP). This 
would ensure product safety and quality and resolve the current issue of 
adulterants. All MDMA products would be labelled with clear indications 
for dosage, contraindications, and potential adverse events.
• Licensed MDMA products would be sold in government-licensed MDMA 
product outlets. These outlets could be pharmacies in the first instance. 
Pharmacies are uniquely positioned as gatekeepers for controlled drugs. 
Regulated pharmacy sales would enable the retail of MDMA products 
to be governed by strict regulatory legislation and a well-defined quality 
assurance infrastructure.
• Point-of-sale face-to-face discussion is crucial for harm reduction. MDMA 
product outlet staff (initially pharmacists in our incremental model for 
policy change) would be specially trained to educate customers on the risks 
associated with MDMA use. Take-home educational material promoting 
harm reduction would also be available.
• MDMA products would not be ‘on prescription’. Instead, adults who wished to 
purchase MDMA products would be required to obtain a ‘personalised licence’ 
to do so. This licence would only be available to those who had first discussed 
the risks of MDMA use with a trained pharmacist. Personalised licences would 
be conditional on adults being able to demonstrate that they understand the 
risks and how to minimise them. They would be reviewed on an annual basis. 
• The development of adult-only MDMA-friendly spaces could provide 
an environment in which the risks associated with MDMA use could be
Recommendations for a strict state-regulated legal 
market for MDMA products for adults:
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further mitigated through well-established harm reduction measures and 
requirements for on-site medical assistance. These venues would need to 
incorporate procedures to minimise risks and promote responsible MDMA 
use, such as ensuring that dancefloors are cool and well ventilated, and that 
customers exhibiting adverse symptoms quickly receive medical attention. 
Alcohol-free venues could be trialled as a means of encouraging single-
substance use. Alcohol impairs inhibitory control making it easier for people 
who use drugs to consume drugs faster and in higher quantities than they 
had intended. 
 • User controls are essential for supporting the responsible use of MDMA.
Controls would aim to minimise the use of MDMA by vulnerable
populations, reduce polydrug use (including the mixing of alcohol and
MDMA), encourage safer modes and patterns of consumption, and
improve user understanding of the potential harms associated with
MDMA consumption. User controls would include a strictly enforced age
limit, pricing controls, mandated health information on packaging and
at point of sale, childproof and tamperproof packaging, a comprehensive
ban on marketing and advertising, and a campaign to minimise the social
acceptability of driving under the influence of MDMA and to promote
alternatives such as designated drivers.
 • Sales of MDMA would be permitted to adults over 18 years of age.
Prohibitive penalties would be in place to restrict underage sales.
 • Information campaigns focusing on MDMA safety and responsible use
would be central to the development of a regulated legal market. Such
information campaigns would cover all sales outlets and educational
establishments (schools, colleges, and universities), and would include
information on recognising the symptoms of adverse events in relation to
MDMA products and how to manage them.
24
MDMA: Roadmaps to Regulation
 • Thorough monitoring and evaluation of the impact of legislative change 
would be undertaken to maintain an evidence-based approach and allow 
responses ‘on the ground’ to feed back into policy decision making.
Roadmaps to Regulation: MDMA is the first report of its kind to outline a 
comprehensive model specifically for the regulation of MDMA. Implementing 
our detailed and pragmatic recommendations would be a progressive move in a 
policy sphere in which it is risky for those in power to engage in an honest and 
rational manner. Yet they must. We have squandered decades on prohibitionist 
policies which have failed to place the health and well-being of citizens at 
their heart. The time has come to move forward, collectively and carefully. 
We desperately need a mature approach to MDMA which properly protects 
vulnerable members of society, whilst allowing those who choose to consume 
the drug to do so safely. Let us not waste another decade.
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Introduction
MDMAa, available in pill, powder, and crystal form, is one of the world’s most 
prevalent prohibited drugs. Typically consumed in a range of leisure spaces, 
including parties, pubs/bars, nightclubs, and festivals, its desired effects include 
increased energy, euphoria, sociability, and ‘openness’. MDMA is classified as 
a Class A substance under the UK Misuse of Drugs Act (MDA) 1971, as a 
Schedule 1 substance under the UK Misuse of Drugs Regulations 2001, and as a 
Schedule 1 substance in the US under the Controlled Substances Act. The UK/
US position on MDMA – as signatories to the UN International Drug Control 
Conventions – is broadly commensurate with that of the rest of the world. 
The 1961 Single Convention on Narcotic Drugs and the 1971 Convention 
on Psychotropic Substances classified controlled substances in four lists (i.e., 
Schedules) according to their perceived therapeutic value and potential risk for 
‘abuse’. MDMA remains a Schedule 1 drug under these UN Conventions, a 
Schedule reserved for drugs considered to pose the greatest risk to public health, 
with limited or no therapeutic value. This evaluation of MDMA means it attracts 
the highest possible penalties for production, supply, and possession offences. 
a MDMA is an abbreviation for  methylenedioxy-methylamphetamine. Also known as 
3,4-methylenedioxymethamphetamine, MDMA is a ring-substituted phenethylamine 
(compounds based upon the phenethylamine structure), structurally related to amphet-
amines and mescaline. 
Fig. 1
Molecular Structure of MDMA
Source: 
The Beckley Foundation
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Despite long-standing international prohibition, MDMA’s availability and 
popularity remain consistently high. Consumed in more niche party scenes in 
the US during the 1980s (notably in the gay scene), synonymous with rave and 
dance music culture from the late 1980s, and enjoying both sustained popularity 
amongst ageing ravers and a recent resurgence in popularity amongst younger 
dance music fans, MDMA is evidently here to stay. 
The prevalence of MDMA use is captured by general population surveys (GPS), 
targeted population surveys, and other drug monitoring data sources such as 
multi-city analysis of wastewater1, 2, 3, 4. According to the United Nations Office 
of Drugs and Crime, 21 million people are estimated to be past-year users of 
MDMA, with use remaining stable or increasing in Australia and New Zealand, 
Europe, and North America between 2005 and 20175. In the years preceding 
2013, MDMA use had been declining in Western and Central Europe, but more 
recent data show a stabilisation or an increase in its use in countries throughout 
the continent, alongside increases in use in Latin America1, 5. The most recent 
EU-level figures (2019) suggest that 13.7 million European adults aged 15–64 
have used MDMA in their lifetimes (4.1%). Last-year use of MDMA amongst 
European adults aged 15–64 stood at 2.6 million (0.8%), with 2.1 million (of the 
2.6 million) users being young adults aged 15–34 (1.7%)1. National prevalence 
rate estimates of MDMA use among European adults aged 15–64 range from 
Fig. 2
MDMA Crystals
Source: 
Hypnotoad
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0.2% in Portugal and Romania to 7.1% in the Netherlands1. Countries with the 
historically highest prevalence of MDMA use in Europe include the Netherlands, 
the Czech Republic, the UK, Bulgaria, and France6. 
At the global level, millions of people worldwide repeatedly break drug laws 
on possession and supply to access MDMA’s psychopharmacological properties. 
Despite intense local, national, and international policing efforts, significant 
disruption of MDMA production and supply has only ever been temporary 
and localised – with the expanding market more than able to meet the long-
term trend in rising global demand. In this context, the economic and human 
costs of prohibitionist policies towards MDMA are increasingly unjustifiable. 
By preventing access to legal supplies, prohibition has created a profit incentive 
for an entirely unregulated global criminal market in illegal drugs – including 
MDMA – to develop. Those who support prohibition tend to characterise the 
moving of drug policy reform towards a less punitive regime as ‘radical’, and 
as being ‘soft-on-drugs’, or ‘pro-drugs’7. However, historically speaking, it is 
prohibition that is the poorly evidenced and ‘radical’ policy which has allowed 
criminal markets to flourish8. In direct contrast, a legal regulation model – not 
an absolute or blanket prohibition, nor a simplistic free-market legalisation 
model – would enable state institutions and civil society to exercise far greater 
control over drug markets, including the market for MDMA, via evidence-based 
regulatory regimes. To this end, all drug policy reform should be built on careful 
experimentation with innovative policy options routinely evaluated by relevant 
government bodies, civil society, and independent researchers9, 10, 11.
In the context of MDMA’s enduring popularity, this report’s primary aim is 
to serve as a realistic and comprehensive roadmap out of the impasse of failing 
prohibition and towards a safer future for people who use MDMA. Whilst 
others have helpfully produced roadmaps towards dismantling prohibitionist 
policies and building alternative regimes which focus on illegal substances with 
some consideration of specific substances8, this report is unique in its focus on 
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MDMAb. This report is also timely in an era when MDMA use is increasing 
in the UK and across Europe1, MDMA is increasingly available for purchase 
online1, 6, 12, and preventable MDMA-related deaths have risen considerably 
over the last six years in the UKc. Crucially, an evidence-based alternative model 
of future possible MDMA regulation which acknowledges the drug’s specific 
qualities, its user groups, and the circumstances of its use, including polydrug 
used, remains under-explored and largely absent from drug policy debate. This 
is perhaps surprising in light of the enduring press attention given to MDMA-
related deaths and recent media coverage of drug safety testing services at music 
festivals. Roadmaps to Regulation: MDMA fills this gap via a review of MDMA 
research in the UK and beyond, coupled with the policy and scientific expertise of 
the Beckley Foundation, to produce a much-needed in-depth investigation as to 
how an alternative model of regulation of MDMA would work in the ‘real world’.
This report rests on the following five principles which should underpin 
all evidence-informed drug policy and practice: promoting public health and 
reducing harm; safeguarding vulnerable populations, including children and 
young people; supporting human rights; promoting social justice; and supporting 
participatory democracy. 
Roadmaps to Regulation: MDMA has two overarching interlinked objectives:
 • To highlight that the harms associated with MDMA use are predominantly 
related to its prohibition
b For a notable exception, please see Transform Drug Policy Foundation. After the War on 
Drugs: Blueprint for Regulation. Regulated Drug Markets in Practice: MDMA. Bristol: 
Transform Drug Policy Foundation; 2009. pp.140–144.
c  This issue is covered in more detail in later chapters of this report.
d Polydrug use is the use of more than one type of drug (including alcohol) taken at the 
same time (simultaneous use), or more than one type of drug being taken within the same 
period of time, for example, in the last year (concurrent use).
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 • To propose an alternative regulatory model that would reduce the harms 
associated with criminalising MDMA use and minimise the risks associated 
with its use more generally. 
Roadmaps to Regulation: MDMA is divided into three chapters.
Chapter One offers an overview of the history of MDMA, its use as both a 
therapeutic and recreational (non-medical) druge, and a discussion of the current 
legal and socio-cultural context of MDMA use. 
Chapter Two explores the harms associated with MDMA and how they 
are significantly related to its prohibition. The harms associated with MDMA 
and its prohibition are situated in three main areas: production, distribution 
(supply), and use. These relate to both the therapeutic and the recreational 
(non-medical) use of MDMA, and occur at all levels of society. In this chapter 
we examine two ongoing and well-publicised controversies around MDMA 
which are commonly marshalled to argue for continued prohibition, namely 
‘high-strength’f and ‘adulterated’ MDMA products. A careful and considered 
e We recognise that making a clear delineation between ‘therapeutic’ and ‘recreational’ use 
may be problematic, because in many cases there are overlaps, and what would commonly 
be termed ‘recreational use’ may in fact be accompanied by therapeutic intentions and 
results. Nevertheless, we have chosen to use the term ‘therapeutic use’ to refer to MDMA 
administered in a clinical environment, in conjunction with psychotherapy or another 
form of therapy, and recreational use to refer to any use not specifically for medical or 
therapeutic purposes.
f The term ‘high-strength’ in reference to MDMA pills is problematic in that experiences 
of ‘strength’ vary according to user characteristics, e.g., gender, those of lower weight, or 
those with liver conditions. What may be experienced as ‘strong’ by one user may not be 
experienced as such by another. Potency (rather than strength) is a more transparent and 
meaningful term. High/low-potency MDMA pills, crystal, or powder are relative terms 
of comparison. Potency conveys that the ‘amount’ of MDMA is crucial, with a ‘high-dose’ 
MDMA pill sitting anywhere between 100 mg and 400 mg. Acknowledging variability 
between individual users remains crucial.
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analysis of both controversies further demonstrates how prohibition is failing 
to control MDMA and instead exacerbates harms.
Chapter Three details how to implement an incremental move away from 
this failing prohibitionist model of the past towards an alternative model of 
legal regulation. It is argued that this can best be achieved via a flexible and 
evidence-based two-stage process, moving from the rescheduling of MDMA 
and the decriminalisation of all drugs including MDMA, towards the creation 
of a government-regulated legal market for MDMA products, supported by 
investment in proven health and harm reduction interventions. 
Terminology: MDMA or Ecstasy?
MDMA is known by many as ‘Ecstasy’ (in the UK and US) or ‘Molly’ 
in the US. There remains considerable confusion about the terms, so we 
have used MDMA throughout this report. Whereas MDMA typically 
(but not exclusively) depicts the abbreviated version of a single chemical 
compound, ‘Ecstasy’ often refers to tablets containing MDMA alongside 
other components. Many government agencies (including the UK’s Home 
Office and the Office of National Statistics) use the (unscientific) term 
‘Ecstasy’ in their statistical reports. We have chosen to use the term MDMA 
because that is what we would be dealing with in a legally regulated 
market, and because the term ‘Ecstasy’ is commonly associated with tablets 
containing mixed and substances, often a small amount of amphetamines 
to supply extra energy.  
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1 . 1 The history of MDMA: A therapeutic and recreational drug
Chapter One 
MDMA, Past and Present
MDMA was first synthesised in 1912 by the Merck pharmaceutical company 
as an intermediate in the synthesis of another drug13, 14. Its unusual effects in 
humans remained unrecognised for decades. A pivotal moment in MDMA’s 
history came in the mid-1970s when psychopharmacologist Alexander Shulgin 
was informed by self-experimenting students that MDMA had ‘emotional’ 
psychoactive effects worthy of further study. Shulgin, famous for systematically 
creating and describing numerous psychoactive substances, synthesised and tried 
the drug himself. Producing the first report on the effects of MDMA in humans, 
Shulgin and co-author David Nichols noted that the drug produced ‘an easily 
controlled altered state of consciousness with emotional and sensual overtones’15.
Fig. 3
Alexander Shulgin
Source: 
Amanda Feilding
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Recognising its potential for therapeutic usea, Shulgin introduced the 
drug to psychotherapist Leo Zeff, who subsequently achieved success with 
MDMA-assisted psychotherapy, and was instrumental in spreading word of 
the drug among therapists16. Many of those working with MDMA believed 
that it enhanced empathy and communication in patient sessions, and helped 
patients to achieve new and positive insights about their problems. Because of 
consistently reported experiences of feelings of connectedness and empathy, 
the term ‘empathogen’, meaning generating a state of empathy, was coined to 
describe MDMA and other chemically related compounds. This term was later 
discarded by several prominent researchers in favour of ‘entactogen’, meaning 
‘touching within’ to avoid the negative associations with pathogen or pathogenesis17. 
From the 1970s until 1985, when MDMA was placed into Schedule 1 by 
the US government, an estimated half million doses were administered in 
psychotherapeutic settings18. During this period there were no associated 
fatalities, and only eight related emergency room visits reported19. No controlled 
clinical trials on its safety and efficacy were conducted at that time. However, 
the onset of prohibition was greatly regretted by therapists and patients alike. 
MDMA’s proposed scheduling in the US was opposed by a group of 
physicians, researchers, and therapists, who presented evidence of its therapeutic 
potential at a Drug Enforcement Administration hearing in 1985. The Drug 
Enforcement Administration’s administrative law judge who led the hearings 
concluded that MDMA should not be placed in Schedule 1 due to its therapeutic 
utility and low potential for harm and abuse. His decision was overruled and 
MDMA’s therapeutic use was prohibited. Early supporters of therapeutic 
MDMA protested that drug-war paranoia led to the premature banning of 
a potentially useful drug with significant benign applications. The restrictive 
scheduling of MDMA stifled research into its clinical potential, and research 
a See Chapters Two and Three for more detail about the potential benefits of the therapeu-
tic use of MDMA, which relates to our call for the rescheduling of MDMA in Phase 1 of 
the roadmap to regulation.
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during the 1990s almost exclusively focused on MDMA’s potential harms. 
However, in 1995 Charles Grob published the first double-blind, placebo-
controlled dose-response safety study of MDMA, showing that MDMA could 
be safely administered within a controlled clinical environment20. Despite 
the bureaucratic hurdles created by the restrictive scheduling of MDMA 
(as discussed in Chapter Three of this report), research is progressing with 
positive preliminary results. MDMA-assisted psychotherapy is currently being 
investigated for use in the treatment of conditions including post-traumatic 
stress disorder (PTSD)21, 22, social anxiety in autistic adults23, and alcoholism24.
Outside of the clinical context, the drug established a wider appeal beyond 
the therapeutic uses first identified by Shulgin. Marketed as ‘Ecstasy’, the non-
therapeutic, recreational use of MDMA began to grow during the 1980s. With 
the explosion of acid house music and rave culture during the ‘Second Summer 
of Love’ in 1988/89, MDMA became a popular psychoactive substance in the 
UK and beyond25, 26. Acid house and rave culture in the early 1990s matured 
into a significant global youth culture with dancing on MDMA at its centre27, 
28, alongside the use of other drugs such as amphetamine (‘speed’) and LSD 
(‘acid’)29. The feelings of ‘openness’, generosity, euphoria, and energy engendered 
by MDMA30 have proved popular amongst music-loving party-people. As 
Reynolds succinctly writes, ‘MDMA turned out to have a uniquely synergistic 
interaction with music, especially up-tempo, repetitive electronic dance music’28. 
However, MDMA was not only used at raves, but also had a much broader 
appeal, notably within gay party scenes in the US.
In the UK, the control measures taken against acid house parties and raves 
in the late 1980s and throughout the 1990s were unprecedented, and so may be 
explained as an indication of their disruptive presence and as a historical 
continuation of the criminalisation of ‘dancing on drugs’31. The 1994 Criminal 
Justice Act criminalised gatherings of more than fifty people (later reduced to 
ten) listening to ‘amplified music’ characterised in the legislation as a ‘series of 
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repetitive beats’. Despite widespread ‘fight for your right to party’ protests by 
young ravers across the UK, the legislation was passed. However, raves had 
already moved from abandoned warehouses, urban wasteland sites, and farmers’ 
fields into both ad hoc and purpose-built dance club spaces such as Ministry of 
Sound in London, which obtained the first UK twenty-four-hour music-and-
dance late licence in 199032. 
Over the past three decades, global dance cultures linked to MDMA use have 
been both profoundly commercialised33 and criminalised (e.g., police raiding licensed 
dance events; police sniffer dogs at dance events). Today, dance cultures involve 
millions of avid fans across the globe dedicated to an eclectic array of dance music sub-
genres. In recent years we have seen the enduring appeal of house music, the growth 
and maturation of European techno and trance music scenes, and the emergence 
of contemporary electronic dance music (‘EDM’) in the US. In part related to the 
enduring appeal of dance music cultures, demand for MDMA has remained a 
strong feature of the global drugs landscape, with UK researchers highlighting the 
persistence of MDMA use and related ‘poverty of policy’ for its users34.
MDMA has a special place in the hearts of many dance music fans. The 
‘smiley face’ symbol that became an icon of the late 1980s rave scene is redolent 
Fig. 4
A festival
Source: 
Pixabay
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of the intimacy and general bonhomie still experienced at contemporary events 
whilst under the influence of MDMA. Any policy response to control the use 
and reduce the harms of MDMA must be based on an understanding of the 
material and symbolic role the drug has played – and continues to play – in 
local and global dance music cultures, youth cultures, and youth identities more 
generally35, 36. The UK Criminal Justice Act 1994 is an example of the failure of 
governments to develop nuanced and effective policy responses to global youth, 
music, and drug cultures. 
If there is one vital lesson to be learned from recounting the history of 
MDMA, it is that the specific ‘setting’ in which MDMA is consumed is crucial 
to the risk profile of the drug and the risks users face37, 38, 39, 40, 41. Contemporary 
dance spaces (mainly indoor, with alcohol readily available) have considerably 
different risk profiles for people who use MDMA than the rave spaces of the 
past. As illicit rave culture became rapidly commercialised and criminalised, 
party-people moved into the hot and sweaty spaces of indoor nightclubs, non-
air-conditioned warehouses, and large commercial outdoor festivals. Whilst the 
move to licensed indoor venues did reduce some of the risks of large unlicensed 
rave events, which included a lack of adequate security, welfare, and health and 
safety measures, it was not all good news. Dehydration and overheating emerged 
as potential risks, linked to a lack of available drinking water and poor venue 
temperature control in commercial venues (these issues are covered in more 
detail in Chapters Two and Three). 
The acid house parties and illegal raves of the late 1980s and 1990s were 
often ‘dry events’, meaning alcohol was not always readily available to purchase. 
Today, the norm is for alcohol to be available at music venues and events where 
MDMA use is also prevalent. As rave culture was brought into licensed venues 
in the early 1990s and growing numbers of young people abandoned alcohol, or 
at least reduced their use of it in favour of MDMA, the alcohol industry made 
significant inroads into what had previously looked like a shrinking market. 
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They did this by lobbying the UK government to curtail raves and by adapting 
their marketing of alcoholic drinks, describing their effects as similar to the 
‘psychoactive effect’ of illegal drugs. Marketing strategies included co-opting 
the visual culture of the dance music scene into alcohol branding and marketing, 
often in conjunction with highly sweetened alcoholic drinks (so-called ‘alcopops’) 
and premixed bottled cocktails or shots designed to appeal to youth consumers 
in night-time party environments42.
The 2000s saw the emergence of a ‘new culture of intoxication’43 which 
encouraged binge drinking, a culture which continues today in many UK towns 
and cities44. Alcohol-focused leisure spaces dominate the UK’s night-time 
economy (NTE), with large food and drink chains purchasing buildings in 
urban centres to offer ‘food and booze’ to customers. Independent music venues 
have either been closed or remain under threat of closure as commercial, retail, 
and residential developers buy up increasingly lucrative land in urban centres. 
Despite these changes, for many people there remains no satisfactory substitute 
for the physical and mental effects of MDMA in tailor-made multisensory 
music-focused environments. The demand for MDMA has been resilientb, 45, 
despite the heavy marketing of alcohol in the UK’s NTE and a changing UK 
drug landscape characterised by such developments as the rise in powder cocaine 
use since 2011/12, and the fall in cannabis use amongst young people over the 
past two decades45, c, 46, 47.
Another lesson we can learn from the history of MDMA is how the drug 
needs to be understood in relation to other drugs such as alcohol (as outlined 
b There was a significant increase in last-year use of MDMA among 16–24-year-olds in 
England and Wales between 2011/12 (3.3%) and 2017/18 (5.1%) (Flatley 2018).
c In England and Wales between 2011/12 and 2017/18, last-year use of powder cocaine 
increased from 2.1% to 2.6% among 16–59-year-olds, and from 4.1% to 6.0% among 
16–24-year-olds (Flatley 2018, p.5). Last-year use of cannabis among 16–24-year-olds 
peaked in 1998 (28.2%), had more than halved by 2012/13 (13.5%), and now stands at 
16.7%.
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above) and cocaine when consumed in private, semi-private, and public spaces of 
recreational drug use48, 49. Polydrug use, such as cannabis use before, during, and 
after MDMA use on a night out, has long been the norm. As previously noted, 
amphetamines and LSD were also prevalent in the early rave days. In fact, in a 
study of polydrug use conducted amongst nearly 5,000 participants who regularly 
attended UK dance music events in 1999, under 4% took MDMA on its own, 
whereas 77% took it with amphetamines, 75% with cannabis, and 63% with 
tobacco50. MDMA may have fuelled the emergent rave scene, but other (often 
cheaper and easier to access) legal and illegal drugs have historically played their 
role too, as they continue to do today. Alcohol use and, more recently, powder 
cocaine use are prevalent across contemporary NTE spaces, which include dance 
spaces. The fact that MDMA is frequently but one of a range of drugs (including 
alcohol) fuelling a night out dancing has crucial policy implications. 
Over the past three decades, the availability, purity, and potency of MDMA 
has been variable. In the UK from 2008 to 2012, access to MDMA of reliably 
consistent potency and purity decreased. This was likely due to an international 
crackdown on the sale and distribution of safrole/sassafras oil, a key precursor in 
the manufacturing of MDMA. Synthetic safrole was internationally prohibited 
in 1992 due to its role in MDMA productiond, but safrole oil derived from 
plant sources remained uncontrolled and legally available due to its use in 
the production of fragrances, cosmetics, and pesticides. In 2006 Cambodian 
authorities were encouraged to control safrole oil due to its association with 
MDMA production and issues concerning the sustainability of the mreah prew 
phnom tree (internationally identified as Cinnamomum parthenoxylon) from which 
the oil was being illegally extracted. Large quantities of safrole oil were seized by 
international law enforcement agencies: in 2008, thirty-three tonnes of the oil 
were intercepted and burned in a public ceremony in Cambodia. The number of 
d In 1992, safrole in its pure chemical form was added to the list of controlled substances 
under the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances. See https://www.unodc.org/pdf/convention_1988_en.pdf.
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active safrole distilleries in the western Cardamom Mountains decreased from 
seventy-five to zero between 2006 and 200851. 
The resulting reduction in the supply of MDMA did not eliminate the 
appetite or market for psychoactive drugs. Rather, use was partially displaced 
to newly emergent ‘legal highs’, since termed ‘novel psychoactive substances’ 
(NPS). Dance music clubbers and those attending gay-friendly clubs became 
early adopters of NPS such as mephedrone52, although for some attending gay-
friendly clubs mephedrone was used alongside rather than instead of MDMA53. 
Mephedrone mimics some of the stimulant effects of MDMA54 but poses greater 
acute, sub-acute, and chronic risks, notably a compulsion to re-dose and signs 
of dependency amongst a third of young users who were recruited to the study 
through their involvement in dance music scenes55.
In 2010 the legally available synthetic PMK-glycidate started to be used 
as a pre-precursor, from which precursors such as PMK and safrole can be 
synthesised and processed into MDMA10. As use of this glycidate spread, 
reliable access to more consistently high-quality MDMA grew, and by 2012 
the market had recoverede. In turn, the market for mephedrone contracted 
considerably, although it did not disappear entirely, especially amongst men 
who have sex with men in the UK56. In March 2019, PMK-glycidate, PMK 
glycidic acid and Alpha-phenylacetoacetamide (APAA) were added to the list 
of drugs controlled under the 1988 UN Convention against Traffic in Narcotic 
Drugs and Psychotropic Substances57. It remains to be seen how this ban will 
affect the MDMA market. 
e According to the 2016 report on MDMA by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA), PMK-glycidate, a synthetically produced pre-pre-
cursor, has been identified as one factor revitalising the global market in MDMA from 
around 2010/11 onwards. See p.13 of http://www.emcdda.europa.eu/system/files/publi-
cations/2473/TD0116348ENN.pdf.
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UK MDMA use and consumption practices today
MDMA is the third most popular illegal drug among all UK adults after 
cannabis and cocaine, and the third most popular among young people aged 
16–24 who use drugsf. Around 3 million UK adults (aged 16–59) have used 
MDMA in their lifetimes45, 46, whilst an estimated 300,000 young people aged 
16–24 have taken MDMA in the past year, and over 100,000 in the past month45, 
g. Men are more likely than women to use MDMA29, 46. Young people are more 
likely than adults to take MDMA, and those who frequent UK nightclubs 
(especially four or more times a month) are also more likely to take MDMA than 
are their non-clubbing counterparts45. Polydrug use is a particularly common 
and potentially risky trait reported by MDMA users. For example, 57% of UK 
users reported taking MDMA simultaneously with other illegal drugsh. Where 
MDMA was taken simultaneously, it was most often used with cannabis (64%), 
powder cocaine (47%), and mephedrone (25%)45, 47. Alcohol is also commonly 
consumed with MDMA, most notably in NTE settings and at music festivals 
where alcohol consumption is normalised43. 
Despite its popularity and in marked contrast with many other popular 
legal and illegal drugs such as alcohol and cannabis, occasional use of MDMA 
is typical, whilst intensive use is very rare. Of those UK adults who had used 
MDMA in the previous year, 93% said they used it once a month or less, and 
the proportion of last-year users who took MDMA more than once a month 
f It is worth noting that the prevalence figures for lifetime, past-year, and past-month use 
of MDMA (and indeed of other drugs) as captured by national annual GPS are generally 
recognised to be underestimates given that GPS systematically exclude certain groups of 
young people, notably students and street homeless people.
g Past-month use of drugs is understood as ‘frequent’ use across both GPS and targeted 
population surveys. 
h The issue of both polydrug use and polysubstance use by MDMA consumers is dealt 
with in more detail in Chapter Three where we lay out the two phases of our roadmap to 
regulation.
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has fallen over the last decade45, 46, 47. That intensive use is rare is partially 
related to how MDMA acts on users’ bodies, encouraging the release and 
inhibiting the reuptake of serotonin which brings with it the empathetic, 
euphoric, and energetic effects the drug is known for. However, continued use 
of MDMA in any given ‘session’ offers diminishing returns as the user’s brain 
needs a period of recovery before MDMA can work again. This means that 
MDMA does not lend itself well (if at all) to daily use, with users typically 
restricting their use to specific time-bounded sessions unfolding in pre-club, 
in-club, and post-club spaces, and characteristically at weekends, with at 
least a week-long break in between to maximise the drug’s benefits. However, 
intensive use across short time spans is apparent during clubbing holidays 
and festivals58. Prolonged daily use of MDMA – an indicator of problematic 
use – is atypical and most usually associated with co-occurring mental or 
physical conditions, with only a few cases reported59, 60. Very few people seek 
treatment for problematic use of MDMA. For example, statistics from the 
most recent Public Health England report reveal that, in every year since 2005, 
less than 1% of adults seeking treatment for drug problems cited MDMA as 
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their primary problem drug61. Cannabis and alcohol continue to be the most 
cited primary problem drugs amongst young people in treatment across the 
UK (92%) as compared to ‘Ecstasy’ (3%)62.
For MDMA users, the most common route of administration is oral. Pills, 
capsules, and MDMA ‘bombs’ (a dose of crystal/powder wrapped in a cigarette 
paper) are swallowed. Some users prefer to lick a finger dipped into powder or 
rub it into their gums. A minority use nasal inhalation (‘snorting’) as it results 
in a faster onset of the effects but a shorter high. Injection and other routes of 
administration are used very rarely63, 64. With oral administration, it takes twenty 
to sixty minutes before effects are felt; peak effects are reached between sixty 
and ninety minutes, whilst the total high lasts for around five hours65. Given the 
‘time lag’ between oral ingestion of MDMA and its effects, recent harm reduction 
advice to consume only quarter or half pills, and/or to ‘crush, dab, and wait’ when 
consuming MDMA crystal/powders is particularly important, notably the ‘crush’ 
aspect, which can help users avoid consuming a larger dose than they intend to 
take66. Sticking to quarter or half pills (at least when a new ‘batch’ of MDMA 
pills is bought) has a long tradition amongst experienced users as part of lay 
harm reduction advice adopted by ‘underground’ ravers/dance clubbers67. Given 
the recent proliferation of high-potency pills (discussed below), harm reduction 
advice around the amount consumed is particularly welcome amongst the many 
MDMA users concerned about drug safety.
The existing evidence makes it clear that those who engage in the UK’s NTE 
are more likely to use drugs than those who do not. Similar observations about 
the synergistic relationship between NTEs and drug use have been made by 
European NTE researchers68. UK annual GPS findings reveal that more frequent 
attendance at bars and nightclubs is associated with more recent drug use, with 
‘in the past month’ used as a standardised proxy for recent usei. MDMA use was 
i One example is the Crime Survey for England and Wales, formerly the British Crime 
Survey, which captures annual self-report data on the use of illegal substances.
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found to be significantly higher among those who had visited a pub or bar at least 
nine times in the last month than among those who had not visited a pub or bar 
at all in the last month45. Unsurprisingly given its stimulant and pro-social effects, 
as previously noted, MDMA is strongly associated with nightlife and (dance) 
music settings, such as clubs, festivals, and parties69, 70. However, MDMA-related 
deaths also occur in the home71, serving as a reminder that non-stereotypical 
patterns of use must not be overlooked as particularly at-risk users may have 
atypical styles of use. This also highlights the need to understand MDMA use in 
private/domestic settings as potentially risky (or safer) spaces involving specific 
patterns of drug use, such as the use of ketamine and benzodiazepines (e.g., 
Xanax) to ‘come down’ from the stimulant effects of MDMA.
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Global MDMA use
MDMA use is apparent across all continents72. Whilst this report concentrates 
on the situation in the UK (and to a lesser extent, Europe, the US, Canada, and 
Australia), MDMA use is widespread around much of the world, albeit with local 
specificities. In terms of production and distribution, MDMA is embedded in 
globalised illegal drug supply chains, a point taken up in Chapter Three of this 
report. Western countries, notably in Europe and the US, Canada, and Australia, 
have relatively high rates of MDMA use5. MDMA use is also growing in non-
Western countries with large populations of young people and growing middle 
classes, including China, Hong Kong, India, and Taiwan. In these countries, use 
of amphetamine-type substances (including MDMA) has ‘grown dramatically’5.
Dance music cultures, and the concomitant use of MDMA, are a global 
phenomenon. It is not surprising then that the patterns of criminalisation and 
demonisation of these cultures seen in the UK have been repeated internationally. 
Their social and cultural value from the perspective of their participants goes 
largely unrecognised because of their link to ‘criminality’ in the form of MDMA 
and other drug use. This is one aspect of the continuing politicisation of MDMA 
which has shut down discussion about policy change. In the UK, as elsewhere, 
MDMA is firmly positioned as an inherently ‘dangerous drug’ that kills 
indiscriminately, and so is deserving of its Class A status. This ignores what the 
scientific evidence and user experiences indicate: that MDMA-related harms, 
whilst complex, are at least in part related to consumption patterns (e.g., taking 
too high a dose or mixing it with other drugs) combined with aspects of the 
illegal MDMA market (e.g., no dose control, adulteration). This means that 
MDMA use is rendered far more dangerous than it might otherwise be.
The reputation of MDMA as a dangerous drug means that one of the main 
challenges faced at each stage along the roadmap to regulation is resistance to 
change from political classes and public commentators who see little popular 
1 . 3
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appeal in any change in drug policy that might be framed as going ‘soft on 
drugs’. However, this should not deter policy change. Evidence from comparable 
progressive incremental shifts, such as equality legislation in the UK from the 
criminalisation of homosexuality to equal marriage, or tobacco control up to 
the ban on smoking in public, suggests that public opinion can both lead and 
follow policy change in a virtuous circle. Key objections to reform typically 
involve citing the risks and harms of MDMA use. We now analyse the evidence 
on risks and harms relating to MDMA, and show how those associated with 
MDMA are predominantly related to its prohibition.
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2 . 1 Inherent harms? ‘High-dose’ and adulterated  
MDMA products
Chapter Two
 
MDMA-Related Harms 
Under Prohibition
Drugs differ in the degree to which their risks are intrinsic or contingent on 
circumstance. Optimisation of the political and socio-cultural circumstances in 
which a drug’s use occurs can increase the proportion of users enjoying the drug 
without harm, but only up to a ‘ceiling’, representing the intrinsic, ever-present 
risks of the drug. Tobacco for example has a low ‘ceiling’: a typical person who 
initiates smoking even within a well-regulated environment will nonetheless 
face considerable chronic risks, which include addiction, bodily harm, and 
smoking-associated diseases. MDMA in contrast has a relatively high ‘ceiling’ 
due to its low dependency potential73 and the fact that no specific syndrome of 
chronic MDMA harm has been conclusively identified that cannot be reversed 
with abstinence74, 75. MDMA’s risks are primarily related to acute adverse health 
effects that have been reported following MDMA consumption. However, there 
is currently no consensus on the fatal blood concentration level of MDMA, and 
it is unclear to what extent the harms are attributable to the toxicity of MDMA 
alone, or to the circumstances in which the drug is taken76.
The principal concern in relation to MDMA are MDMA-related deathsa. In 
the UK these peaked in frequency in the early 2000s and then fell from 2005 to 
2010. Between 2010 and 2016 the number of MDMA-related deaths climbed 
every year, from nine in 2010 to ninety-seven in 2016, the highest figure ever 
recorded. Data for the most recent year available (2017) for the UK in its entirety 
(England and Wales, Scotland, and Northern Ireland combined) show a slight 
fall, with a total of eighty-six MDMA-related deaths77, 78, 79. However, as we go 
a It is worth noting that these are called ‘Ecstasy-type product’-related deaths in Scotland.
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to press in the autumn of 2019, the latest figures for MDMA-related deaths in 
England and Wales alone have been released, showing a staggering increase from 
fifty-six deaths associated with MDMA use in 2017, to ninety-two deaths in 
201880. Of these reported deaths, fifty-five were related to MDMA use without 
other drugs, while thirty-seven involved poly-drug use80. The latest data from 
Scotland (2018) also reveals an increase in deaths from the consumption of (what 
the Scottish government calls) ‘Ecstasy-type products’ – from twenty-seven in 
2017 to thirty-five in 2018. However, of the thirty-five deaths, only two were 
reported as being related solely to ‘Ecstasy-type products’81. Data from 2018 for 
Northern Ireland is not yet available.
Statistics for the UK as a whole combine deaths associated with MDMA 
use alone with deaths associated with MDMA use in conjunction with other 
drugs, making it more difficult to determine the precise cause of death. For 
England and Wales, and for Scotland, the numbers are recorded separately for 
both MDMA alone and MDMA with other drugs, but the figure propagated 
by the media and highlighted in government reports is the one that includes the 
use of MDMA with other psychoactive drugs82. This results in an exaggerated 
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depiction of the rate of MDMA-related deaths and obscures the fact that other 
drugs were consumed in many of these reported deaths. It is also worth noting 
that MDMA use in the UK amongst 16–24-year-olds has increased since 
201245, and that this age group is considered to be more vulnerable to some of 
the adverse effects of MDMAb.
The increase in MDMA-related deaths has been mirrored by an increase 
in ‘high-dose’ MDMA/‘Ecstasy’ pills in circulation, and the presence of high-
risk adulterants such as PMA (paramethoxyamphetamine) and PMMA 
(paramethoxymethamphetamine) in pills mis-sold as MDMA, which heighten 
the likelihood of harm to users. Herein lies the irony. Both the lack of control 
over dosage (or rather, the lack of user knowledge about purity to inform dosage 
decisions) and the presence of toxic adulterants, including prohibited NPS83, are 
directly attributable to global and national prohibitionist policies. There is no 
‘inevitability’ about these risks of MDMA use. Rather, risks and potential harms 
b It is also worth noting that whilst women are considered more vulnerable to the negative 
effects of MDMA use, it is men who feature most heavily in UK MDMA-related death 
statistics. This is most likely related to the higher prevalence of MDMA use amongst 
young men as compared to young women.
Figure 7.
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Source: 
Tumblr tesk187
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are emergent in the intersections of law enforcement policies and practice, and 
the vagaries of illegal and unregulated drug markets, alongside user practices 
within varied leisure spaces and times. 
Such nuances are lost on those who seek to maintain the prohibitionist 
status quo84. The risks and emergent harms of MDMA have, for example, 
been uncritically linked to the adulterants PMA and PMMA, mis-sold as 
MDMA. That these adulterants with high risk profiles are only present because 
of unregulated production processes within the illegal market for MDMA is 
ignored by the UK government and most of the British press. The market for 
PMA and PMMA alone is non-existent, yet they are conflated with MDMA and 
presented by the UK government as (further) validation of their uncompromising 
prohibitionist approach, as this statement from a Home Office spokesperson 
highlights: 
MDMA, PMA and PMMA are all illegal Class A drugs. They destroy 
lives, cause misery to families and communities, and this government has 
no intention of decriminalizing them. No drug-taking can be assumed to 
be safe.85
Internationally, media and politicians have voiced concern about MDMA, 
concern which is largely unrepresentative of the risks policy makers should 
realistically be weighing up when considering drug policy. Whilst MDMA 
tabloid stories may be less ubiquitous than they once were, such attention has 
effectively shaped public opinion to the point where, relative to other drugs, the 
risks and potential harms of MDMA use appear over-emphasised, exaggerated, 
and, importantly, are decoupled from the contexts in which most MDMA-
related deaths occur. 
Presently, MDMA doses contained in single tablets and cumulative doses 
consumed during a ‘session’ (drug consumption period) are highly variable. 
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Maximal ratings of desired effects are reported for tablets containing between 
80 and 100 mg of MDMA86. However, for more experienced users, 80–100 
mg may be considered a suboptimal dose. ‘High doses’ may produce undesired 
effects, notably amongst inexperienced, typically young, and/or occasional 
users. It has been found for example that undesired effects predominate above 
single doses of 120 mg for inexperienced and irregular users, but not among 
more experienced and regular users86. Gender is also important in relation to 
vulnerability to potent, high-dose MDMA pills or crystal, as women are more 
vulnerable to certain adverse effects87, 88. Young, female, novice users therefore 
combine multiple vulnerabilities.
The relationship between dose and potential unwanted effects is complicated 
and MDMA use cannot be considered in isolation from the user and the users’ 
setting. However, variability in dose and high-dose (also called ‘high-strength’) 
products heighten the risks. In the illegal MDMA market, individual tablets 
and capsules have been found to contain hugely variable doses. A capsule 
seized from a rave in California in 2010 contained 270 mg of MDMA; twelve 
people suffered life-threatening reactions to MDMA at this single event, two 
of whom died89. Whilst this event was exceptional, it demonstrates the dangers 
inherent in the distribution of MDMA as an illegal and hence unregulated 
product. If these young people had known the dosage contained within their 
pills and had been sufficiently informed to understand the implication of such 
dosages, they may have made different consumption choices and such deaths 
may have been prevented. Serious acute adverse effects and deaths linked to 
MDMA occur through several mechanisms. None of them are as simple as 
an ‘overdose’ and most are preventable through a combination of screening for 
pre-existing medical conditionsc and comprehensive harm reduction advice, for 
example around the risks of water intoxication from excessive water intake when 
c Note that this is suggested as one aspect of a legal access regulation model (see Chapter 
Three) that would include pre-screening for certain pre-existing conditions which render 
users more vulnerable to MDMA. 
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trying to prevent dehydration after taking MDMA (hyponatraemia). Risks 
include serotonin syndrome, liver failure, hyperpyrexia (uncontrolled soaring 
temperature), or hyponatraemia, when levels of sodium in the blood become 
abnormally low and abnormal water regulation causes brain swelling77. 
Dehydration and heatstroke remain key concerns for harm reduction 
initiatives aimed at contemporary MDMA users. Following two drug-related 
deaths at a festival in the South of England in June 2018, Professor Fiona 
Measham, founder of the UK-based drug checking and harm reduction 
organisation The Loop, called for greater responsibility amongst festival 
organisers with regard to the visible availability of drinking water for festival 
goers90, notably during unseasonably hot weather, as people using MDMA can 
be more vulnerable to overheating91. Management of temperature and hydration 
is an important task for people dancing whilst on MDMA, as both overheating 
with dehydration92 and drinking too much water93 have been linked to MDMA 
medical emergencies and fatalities. Experienced MDMA users remain mindful 
of the need for periodic rest, cooling down, moderate water/juice intake, and the 
avoidance of alcohol intoxication before, during, and after an MDMA ‘session’d.
As previously noted, MDMA and its relationship with global rave and now 
post-rave dance music cultures, where (typically young) people attend dance 
music events such as warehouse parties and festivals, have received sustained 
d ‘Session’ is now used in common parlance to denote a period in which MDMA and other 
illegal and legal psychoactive substances are consumed, e.g., across the duration of a ‘big 
night out’. See for example [www.vice.com/en_uk/topic/safe-sesh]
Ecstasy pills handed into The Loop
Figure 8.
Source: 
The Loop
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and typically sensationalist press reporting94. Indeed, inaccurate documenting, 
press misrepresentations, and public misconceptions about MDMA (and indeed 
illegal drugs more generally) is a key challenge for any roadmap to regulation95. 
MDMA-related deaths have historically received considerable media coverage, 
proportionately much more than any other drugs. Forsyth’s classic study of drug-
related deaths in Scotland in the 1990s found that the press reported on every 
single death where MDMA was implicated, whereas deaths related to other 
drugs were less likely to be reported on, with only one in fifty diazepam-related 
deaths and one in three amphetamine-related deaths covered by the media in 
the same period96. More recent research in the UK has found similar imbalances 
and inaccuracies in reporting on drug-related issues97. US harm reduction 
organisations have spent time counteracting press coverage of MDMA-related 
deaths, some of which involves the spreading of misinformation about ‘Ecstasy 
overdoses’ which do not capture the reality of why some people who have used 
MDMA have died98. A more open and honest dialogue about MDMA-related 
deaths is needed, and the troubling relationship between prohibitionist drug 
policies and MDMA-related deaths properly addressed. 
Figure 9.
Source: 
[informationisbeautiful.net]
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Harms associated with use
It is worth stressing that it is hard to assess the risks of consuming a particular 
drug at either the individual or population level outside of its historical and 
cultural context. Large-scale recreational MDMA use has only been studied 
under conditions of prohibition, and so the evidence can only tell us, at best, 
how risky MDMA is in that specific context. Aside from the pre-ban era of 
MDMA use (which was small scale and not systematically studied), recreational 
users have not had access to a pure, standardised MDMA product, so we cannot 
know for certain what harms, at what levels, may be attendant to that scenario. 
However, as of October 2018, unadulterated MDMA has been administered 
to 1,570 participants in clinical research settings investigating the effects of 
MDMA and its potential therapeutic utility99, 100, 101. These experiments have 
demonstrated that single moderate doses of MDMA can be administered safely 
in a controlled environment, producing consistent and predictable responses with 
minimal negative side effects. No serious adverse events that required emergency 
treatment have been recorded102. It is important, however, to bear in mind the 
distinction between the potential harms associated with recreational use and 
those incurred in the clinical setting, where pure MDMA is administered only 
a few times in the context of a supportive psychotherapy session103.
Acute harms and unwanted effects
Commonly reported undesirable effects of MDMA include characteristic 
physiological reactions, such as jaw clenching (‘gurning’), dry mouth, tachycardia, 
shivering, feeling cold, sweating, dizziness, nausea, and increased heart rate 
and blood pressure. More than half of users104 experience a host of other, rarely 
serious, physiological and mood symptoms105, 106, 107, 108. The exact combination 
of effects depends on factors such as dose, frequency of use, lifetime MDMA 
exposure, personal characteristics (e.g., individual differences in drug metabolism, 
pre-existing cardiovascular problems, personal and family history of mental 
2. 2
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illness, etc.), other drugs taken, and the setting. In addition, there are gender 
differences in responses to MDMA, with women reporting stronger hallucinatory 
effects, and being more likely than men to experience certain adverse events109, 110. 
MDMA users most frequently present for emergency treatment with symptoms 
such as dizziness, nausea, or feeling unwell or strange; or arrive having collapsed at 
a venue111, 112. The most common treatments required are monitoring, reassurance, 
and rehydration.
MDMA can lead to more serious acute physical harms. By simultaneously 
increasing metabolic heat generation and impairing heat dissipation through 
vasoconstriction, MDMA typically increases body temperature, an effect that 
can occasionally develop into severe hyperthermia113, which can lead to multi-
organ failure including acute liver failure114. While under laboratory conditions, 
higher doses of MDMA cause an increase in body temperature comparable to 
that experienced during exercise. Hyperthermia is a leading cause of MDMA-
related deaths115. Although deaths from MDMA-induced hyperthermia may 
happen in other contexts116, risks to users are exacerbated by external factors 
associated with indoor raves and nightclubs: the physical activity of dancing, 
coupled with high ambient temperatures and insufficient ventilation, as well 
as overcrowding114.
Another fatal complication related to MDMA consumption is the previously 
mentioned hyponatraemia, when levels of sodium in the blood become 
abnormally low and abnormal water regulation causes cellular swelling in the 
brain. MDMA causes the brain to release hormones (e.g., arginine vasopressin) 
that cause water retention. This can become problematic when users drink large 
amounts of water in an effort to stay hydrated. Evidence suggests that women 
maybe more prone to hyponatraemia than men117.
MDMA use reliably leads to transient increases in blood pressure and 
heart rate, with greater elevations witnessed in male users109. Although in 
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most users these changes are akin to those witnessed during exercise and are 
typically well tolerated118, 119, such increases may nonetheless increase the risk 
of several cardiovascular harms, including stroke, myocardial infarction, and 
subarachnoid haemorrhage120, 121, 122. Although such events are well-established 
complications of hypertension, it is noteworthy that case reports linking such 
events to MDMA use rarely confirm the presence of MDMA, so the true risk 
rate remains unknown. No clinical trial of MDMA has so far recorded any 
such event. 
MDMA is also a powerful releaser of serotonin and when used alongside 
other serotonin-releasing drugs such as the stimulants cocaine and amphetamine, 
or commonly prescribed selective serotonin reuptake inhibitor antidepressants, 
it may cause a rapid, synergistic rise of serotonin (5-HT) concentration in the 
central nervous system. This can lead to the acute and sometimes lethal medical 
emergency known as serotonin syndrome123. Regarding these potential harms, 
it should be noted that it is difficult to establish to what extent these effects are 
specifically attributable to MDMA, because factors such as poly-drug use and 
drug–drug interactions, high dosages, personal vulnerabilities, or the presence 
of adulterants could also contribute to these effects77. 
Sub-acute effects and chronic harms
No specific syndrome of chronic MDMA harm has been conclusively identified 
in recent meta-analyses in moderate users75. Chronic high doses could potentially 
lead to abnormalities in the serotonin system91, 124, although these changes seem 
to be reversible with abstinence125. In the days immediately following MDMA 
use, many users report experiencing negative after-effects, such as low mood and 
anxiety, sleep disturbances, or memory problems126, known colloquially as the 
‘comedown’ or ‘mid-week-blues’. However, the role of MDMA in these effects is 
unclear, as other factors associated with a night out, such as alcohol consumption, 
sleep deprivation and disturbance of circadian rhythms, and poor nutrition and 
2 . 2 . 2
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hydration, can be major contributors127, 128. In contrast, only a small minority of 
people taking pure, measured doses of lab-grade MDMA in the daytime report 
experiencing negative physiological and psychological symptoms in the three 
to five days post-drug129.
Several cases of sub-acute liver failure, in the absence of any hyperthermia, 
have been reported in the days following an MDMA ‘session’, or after months 
of regular use. The precise cause of liver failure in these instances is poorly 
understood, although a number of patients who return to MDMA use 
after recovery experience a renewal of the hepatotoxic effects, suggesting an 
immunological mechanism115. As above, the nature of an unregulated market 
makes it impossible to ascertain whether the liver toxicity in these cases was 
driven primarily by MDMA, another psychoactive compound contained in a 
tablet, some adulterant, or the co-ingestion of MDMA with another substance 
in the context of polydrug use. Across the completed clinical trials using MDMA, 
there have been no recorded incidents of liver disease or hepatotoxicity.
It would be unethical to administer MDMA to humans chronically in a 
controlled experiment, to see what damage might occur when other causes 
(such as adulteration and concurrent use of other drugs) are excluded. This leaves 
us with only a partial understanding of the risks associated with occasional or 
regular use over months, years, and lifetimes. The available evidence comes from 
animal experimentation, observational studies of human users, and accounts of 
harm, such as case reports. On the basis of these studies, some experts believe 
that chronic high-dose MDMA use can cause neurological, psychological, 
and mood problems; sleep problems; and cognitive impairments76, 108, 130, 131, 132, 
and claim this is likely the result of direct neurotoxicity133, 134. However, such 
neurotoxic effects have been challenged by others on various grounds75, 76, 108, 
135, 136. In 2018, it was found that many previous brain-imaging studies on the 
neurotoxic harms of MDMA use have disproportionally recruited unusually 
heavy users as participants137. Research participants in ten key studies had 
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consumed on average 720% more MDMA pills than typical users captured 
by for example the 2015 Global Drug Survey138. The implications of this study 
are that the conclusions of some of the neuroimaging literature on MDMA 
may significantly overestimate the extent of serotonergic alterations related to 
more moderate patterns of MDMA use that characterise most consumers. The 
translatability to humans of studies producing evidence of harm in animals is 
likewise questionable, as many involve regular and high doses of MDMA that 
do not reflect typical user behaviour139. 
Meta-analyses, when data are pooled to increase the reliability of findings, 
tend to support the existence of statistically significant but subclinical deficits in 
cognitive performance among at least the most regular MDMA users, i.e., they 
may perform slightly worse than controls on specific tests (e.g., recalling lists 
of words), but remain within the normal range108, 140. However, sources of bias 
have been identified in these data that still prevent certainty. When samples of 
MDMA users are compared with non-users and found to show deficits, findings 
are muddied by the fact that most people who use MDMA also use one or more 
other drugs. In a study designed explicitly to sample only those people who use 
MDMA who do not use other drugs, the link to deficits disappeared141. After 
more than 25 years of research, the spectrum of expert opinion shows no signs 
of narrowing into consensus. For an illustrative example of such discussion read 
Parrott (2013)63 and Doblin et al. (2013)142. 
There is some evidence from both animal and human studies to suggest 
that reduced serotonin levels following maternal MDMA use can adversely 
affect foetal development. Although rats exposed to MDMA during pregnancy 
will bear pups of normal weight and without birth defects143, the pups of mice 
exposed daily to high levels of MDMA during pregnancy are more likely than 
controls to display abnormalities144. In mice, the lowest amount of maternal 
MDMA exposure which led to detected offspring abnormalities was 5 mg/
kg/day, equivalent to a 60 kg pregnant woman taking 25 mg of MDMA every 
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day. This pattern of exposure is unlike any reported usage trend in humans, and 
as such, while the animal literature has identified that MDMA exerts some 
developmental toxicity, it is insufficient to provide a clear picture of how typical 
patterns of MDMA use may harm a developing foetus. Self-report surveys 
investigating drug use in pregnant mothers145, 146 have found that poorer motor 
development at four months is predicted by prenatal MDMA exposure, with 
more heavily exposed infants performing less well than infants with lower, or no 
exposure. While more research is required to say conclusively, these differences 
in development may ultimately resolve as infants grow: by twenty-four months, 
it was only infants with heavy prenatal exposure to MDMA that displayed 
detectable differences from normal motor development. Mothers of these infants 
reported taking an average of 1.7 tablets of ecstasy per week during pregnancy, 
an amount far in excess of most recreational users.
Long-term cardiovascular effects of MDMA use appear to be limited 
to the heaviest users. In a small study of eight MDMA users with lifetime 
exposure of between five and 200 doses, echocardiographic readings revealed 
no abnormalities147. A sonographic investigation of the hearts of twenty-nine 
MDMA users found cardiac abnormalities indicative of potential valvular 
heart disease only in those people reporting lifetime cumulative doses of 900 
tablets, compared to the average 200 lifetime doses among those with no cardiac 
abnormalities148. 
A crucial driver of chronic drug harm is dependency. The potential for 
chronic harm from a drug is limited when users can make a free choice to reduce 
or cease use as soon as they feel that the costs outweigh the benefits. This is 
the pattern documented for MDMA. MDMA use appears to be largely self-
limiting: at first, users may escalate their doses as users of dependency-forming 
drugs do, increasing the associated risks. However, in contrast to patterns of 
use for other drugs, when the cost–benefit balance becomes negative, people 
who use MDMA spontaneously reduce or stop using149, 150. Other people ‘grow 
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out of it’ and the dance club scene of which it is a part151. Although some users 
report ‘cravings’ (but not withdrawal symptoms), several lines of evidence suggest 
that MDMA has relatively low addictive potential, a conclusion supported by 
the very low rates of identifiable dependent or problematic use (much less than 
1% of UK adults presenting for treatment)152, 61, despite it being the third most 
commonly used drug in England and Wales45. 
However, the evidence on MDMA’s addictive potential is not unequivocal, 
and a different interpretation is possible. Presentation to treatment statistics may 
be misleading, as one study suggested that MDMA users are less inclined to seek 
treatment than are users of other drugs63. Animal studies indicating only a mild 
reinforcing effect of MDMA may be of limited relevance, as they tend not to 
reflect patterns of use accurately in humans. Whereas rodent self-administration 
studies involve single-drug use and intravenous administration, human users 
often engage in polydrug use, and typically ingest or snort MDMA153. These 
differences, as well as ‘bingeing’ and high-dose use, may affect the potential for 
dependency in humans154. Further investigation is needed to better characterise 
the risk of dependency in humans, or other harms that are as-yet unrecognised, 
e.g., the potential link between MDMA and heart-valve problems149.
Even the gravest assessments of the burden of chronic MDMA harms to 
society described in the published literature are relatively minor compared to 
those of drugs such as alcohol and cocaine with which MDMA often shares 
space in the recreational drug scene. It would however be misguided to assume 
that because the evidence linking MDMA use to chronic harms is equivocal, 
such harms do not exist or do not matter. Perhaps the best reason to take chronic 
MDMA harms seriously is that users themselves generally do. In the major 
online drug user forums, there seems to be near universal consensus that regular 
MDMA use can become problematic155. Only 1% of adults in England and 
Wales who took MDMA in the last year think that it is ‘ok’ to do so frequently, 
whilst the majority of adult users of MDMA (68%) took the drug once or twice 
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a year45. That figure, along with the fact that most users do not use regularly, 
supports a view of people who use MDMA as rational agents who balance their 
perception of risks and rewards, rather than irrational hedonists who are only 
discouraged from unrestrained consumption by continued prohibition. 
Generations lost: The harm of inaction
Another key harm associated with the prohibition of MDMA is the harm of 
inaction in the face of emergent drug problems and drug-related deaths, when 
there are well-established policy options available that could have prevented 
them. The UK’s Misuse of Drug Act (MDA) 1971 established the Advisory 
Council on the Misuse of Drugs (ACMD), an independent, non-departmental 
public body of experts from a variety of backgrounds. According to the MDA, 
the ACMD is duty-bound to give recommendations to the government ‘on 
measures (whether or not involving alteration of the law) which in the opinion 
of the Council ought to be taken for preventing the misuse of such drugs or 
dealing with social problems connected with their misuse.’ In 2008 the ACMD 
undertook a thorough review of the harms of MDMA and its legal status, 
including an appraisal of the scientific evidence available at the timee,and 
extensive written and oral evidence from experts from a wide range of disciplines. 
The result of these efforts was a comprehensive report published in February 
2009 which is very clear in terms of its findings and recommendations156. The 
recommendations to government are summarised below: 
 • Continuation of a harm-minimisation approach to the widespread use of 
MDMA to be ensured
 • Access to the Safer Nightlife157 guidance to be provided for those who work 
within the NTE
 • Young people to receive adequate education on the risks of using MDMA 
e The twelve-month ACMD study included a review of 4,000 academic research papers on 
MDMA. 
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to support and encourage abstinence
 • Parents/carers, teachers, and those working in the criminal justice system to 
be informed about the risks of MDMA and how these compare with those 
of other drugs (notably powder cocaine)
 • Better data to be captured regarding the form and constituents of seized 
MDMA
 • MDMA to be re-classified as a Class B drugf
 • Research to be expanded into the effects of MDMA upon brain mechanisms
 • Better data to be captured regarding the nature and extent of MDMA use 
in under-16s
 • Further research to be undertaken to quantify the relative risks of, and public 
attitudes towards, MDMA in comparison to other drugs
 • More information to be gathered on the risks and harms resulting from 
polysubstance and polydrug use
 • More research to be carried out focusing on the role of vulnerability factors 
that make individuals prone to the harms of MDMAg
 • A national scheme to be developed for the purposes of testing MDMA with 
a view to providing harm reduction advice and developing monitoring datah
 • Research into the medicinal uses of MDMA not to be disadvantaged by 
the legislation and the position of MDMA in Schedule 1 of the Misuse of 
Drugs Regulations (MDR) 2001
f MDMA remains a Class A substance under the UK’s MDA 1971 after the government 
indicated that it was not prepared to reclassify it despite the ACMD’s recommendation.
g For example, around the role of gender and body mass in instances of water intoxication 
following excessive water intake related to MDMA use. 
h This recommendation directly referenced the Dutch Drugs Information and Monitoring 
System (DIMS), which remains a world leader in multidata harm reduction best practice. 
Ten years after the publication of the ACMD’s review, inroads have been made in relation 
to on-site drug testing regimes by UK drug charity The Loop. In the event of decriminal-
isation, such drug testing regimes should be extended. 
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Each of the recommendations, except for the last, focused on reducing 
individual and social harms related to (recreational) MDMA use. However, 
nearly a decade on from the ACMD’s review, we have witnessed the pernicious 
emergence of NPS, a rise in MDMA prevalence (notably amongst young people 
aged 16–24), and a rise in MDMA-related fatalities, at least in part related to 
prohibition which increases the market presence of adulterated products and/
or unregulated high-dosage products. These developments demand ever greater 
urgency in moving towards the first phase of our roadmap to regulation. Inaction 
is no longer an option given the likelihood that retaining the status quo will lead 
to more MDMA-related deaths. 
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2 . 4Harms associated with production 
Estimating the size of illegal markets is notoriously difficult to do, with indirect 
measures such as police seizures and prevalence data (from surveys or wastewater 
analysis) generally acting as a proxy. The most recent EU-level estimate suggests 
that around 2.1 million European young adults (aged 15–34) used MDMA 
in the last year (1.7% of this age group), with national estimates ranging from 
0.2% in Portugal and Romania to 7.1% in the Netherlands1. Countries with the 
highest prevalence of MDMA use in Europe include the Netherlands, the Czech 
Republic, the UK, Bulgaria, and France1. A recent estimate placed the minimum 
retail value of the illegal MDMA market in the EU at around €0.7 billion, a 
modest figure comprising only 3% of the overall illegal drug trade1. National data 
are exceptionally sparse. A 2006 report commissioned and published by the UK 
Home Office estimated the total value of the MDMA market in England and 
Wales to be £181.9 million–£353.7 million158. The production cost of MDMA 
is between €0.25 and €0.40 per tablet, but the cost to the European consumer 
is normally between €6–€10 per pill1.
While reliable information is hard to come by, experts suggest that MDMA 
precursors are mostly obtained from China (and to a lesser extent Southeast 
Asia), with most production operations taking place in the Netherlands, Belgium, 
and Canada. Overall, the MDMA market is one of increasing sophistication 
and scale, with a production chain involving multiple locations, countries, and 
stakeholders1, 159, 160. Evidence concerning the production of MDMA in illegal 
lab settings is patchy at best, but police and journalistic reports from around the 
globe shed some light on the risks for both producers and users. The available 
information from seizures suggests that at least some clandestine production takes 
place in improvised, small-scale underground labs that lack the necessary quality 
or safety controls and adequate materials161. This can introduce adulterants, either 
intentionally to ‘bulk up’ the product, or as a by-product of sub-optimal synthesis.
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The synthesis of MDMA in such places is also carried out by individuals 
who may lack advanced knowledge of, or concern for, best practice in practical 
chemistry, increasing the likelihood of product adulteration and inconsistency, 
as well as the likelihood of accidents that harm lab workers, such as burns or 
inhalation of toxic fumes162, 163. On the other hand, there is a rise in a more 
sophisticated industrial-scale operation with innovative production methods 
and precursors that challenge the global control regime164. The producers have 
reportedly become more flexible and adaptable to changing demands. They have 
customised equipment and automated production in order to expand the scale of 
production to meet the increased demand6. Some routes of synthesis for MDMA 
involve sourcing precursor chemicals that are themselves produced in a context of 
illegality and associated with significant environmental damage. Ecological risks 
are compounded by the lack of waste disposal standards, often leading to the 
contamination of streams and soil165. This is especially relevant given the recent 
diversification in the use of precursor chemicals and increase in production. For 
example, it is estimated that making 1 kg of MDMA results in 6–10 kg of toxic 
waste. This waste is then disposed of in environmentally damaging ways, such 
as being poured down the sink or toilet, dumped in a forest or field, loaded in 
stolen vans or lorries, buried underground, or dumped into the sea6. This creates 
yet another source of harm for members of the general public unconnected to 
the drugs in question. For example, in August 2015, four children were taken 
to hospital with chemical burns after cycling through a pool of liquid caustic 
waste from a synthetic drug production site in Belgium166.
Harms associated with the product
As we have identified previously, the variability in the quality and potency of 
MDMA heightens the risks of harms. Partly due to their clandestine production 
at multiple sites in the context of global prohibition of MDMA, the contents 
of pills and powders sold as ‘Ecstasy’ vary widely167. Studies in 2011 found that 
the amount of MDMA in pills sold as ‘Ecstasy’ ranged from 0 mg to upwards 
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of 240 mg168, 169, with the most recent tests by drug-testing and harm reduction 
charity The Loop170 from the UK festival and nightclub scene identifying pills 
with MDMA content as high as 350–400 mg171. This makes them significantly 
more potent than in previous years, when the average pill contained about 100 
mg of MDMA, and some contained less than 50 mg172. In June 2018, the Greater 
Manchester Drug Early Warning System, in conjunction with the Greater 
Manchester Police and the popular Parklife Festival in North Manchester, issued 
a warning on ‘High potency MDMA (Ecstasy)’173. It is noticeable that issues 
of high dosage, polysubstance/polydrug use, and overheating are all covered in 
the warning. Pills sold as ‘Ecstasy’ contain adulterants, some of which may 
themselves be psychoactive and/or toxic. As users are unaware of the content of 
their pills, this is a potential source of risk, notably when used with other 
substances such as alcohol64, 174. The lack of any consistency of product is also a 
barrier to stable social norms and individual habits of moderate use. 
Periodically, notably between 2006/7 and 2011/12, there have been episodes 
of particularly low reliability of MDMA on the market, likely in response to 
supply-reduction enforcement of the MDMA precursor safrole/sassafras oil, as 
noted earlier. Such fluctuations have several potentially harmful consequences, 
including adverse effects related to other psychoactive, and potentially toxic, 
Figure 10.
High potency MDMA (Ecstasy) Warning
Source: 
[parklife.uk.com]
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adulterants, as well as changes in potency. The emergence of pills contaminated 
with PMA/PMMA is a powerful case which highlights the unintended 
consequences of prohibition drug law enforcement. The effects of PMA/PMMA 
have a slower onset than MDMA, potentially misguiding users into a sense that 
the product is weak and leading them to re-dose. However, PMA and PMMA 
are far more toxic than MDMA, and a double dose can lead to agitation, seizures, 
and hyperthermia. Casualties of these drugs intended to take MDMA175, making 
this perhaps the starkest example of a potentially deadly risk that is entirely 
avoidable through the availability of a regulated and hence reliable legal product. 
Although PMA/PMMA has since largely disappeared, its use as an adulterant, 
even if only temporary, demonstrates the risks of having criminal entrepreneurs 
in control of the supply. A similar scenario could easily happen again with 
another adulterant, and even one rogue batch can cause multiple casualties. 
Diversification is evident in MDMA product branding. There is a broad 
variety of novel shapes, colours, and logos, suggesting competition and more 
active marketing. The Dutch police reported an increase in the number of 
Figure 11.
Tweet from The Loop warning about 
extra potent ecstasy pills
Source: 
The Loop
67
Chapter Two: MDMA-Related Harms Under Prohibition
new tablet designs, from 50 new designs identified in 2012 to 174 in 2014176. 
‘Ecstasy’ pills are often produced and branded for specific events or festivals 
in an attempt by pill manufacturers to ensure that their pill is recognised 
by festival-goers as a marketing ‘tie-in’. For example, high-dose (> 250 mg) 
MDMA pills displaying the logo ‘ADE’ were produced for the Amsterdam 
Dance Event 2015177. However, there is a danger with such branding, whereby 
if a pill becomes popular, copycat versions appear. This does not guarantee 
consistency and continuity, but rather adds to the unpredictability for users. 
In sum, a significant proportion of MDMA-related medical emergencies and 
deaths are cases of accidental poisoning through unintentional excessive doses178, 
179 and/or adulteration with or substitution of other substances180. These clearly 
identified risks flow directly from the illegal production regimen that current 
prohibitionist policies promote. Only legal regulation of MDMA products 
would properly tackle unknown potency, adulteration or use of adulterants, and 
unregulated branding. 
In the last decade, NPS have been developed and marketed as ‘legal’i 
substitutes for MDMA products, although experienced drug users report that 
none have yet achieved the lasting popularity of MDMA. Piperazines, such as 
mCPP (meta-Chlorophenylpiperazine), BZP (benzylpiperazine), and TFMPP 
(trifluoromethylphenylpiperazine) have been sold as ‘Ecstasy’ or ‘party pills’. 
Benzofurans such as 5-APB (5-[2-aminopropyl]benzofuran) have also emerged 
as a supposed MDMA substitute, given their stimulant and ‘empathogenic’ 
properties. Research on the pharmacology of these substances is limited, but 
nothing suggests they are less risky than MDMAj. In contrast to these often 
cheaper ‘unknown white powders’, there is currently a relatively stable supply 
of MDMA products, with prices holding fairly constant since 20101. Under 
i Although these ‘legal highs’ – more appropriately NPS – are now controlled by the Psy-
choactive Substances Act 2016, there continues to be a significant market for these drugs 
amongst the most marginalised populations in society such as prison and homeless pop-
ulations. The NPS market in the UK is now entirely under the control of criminals.
j However, to date no known deaths have been related to BZPs.
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prohibition, criminals exploit this market for huge profits. Hence, another crucial 
aspect of MDMA-related harms relates to the drug’s illegitimate distribution 
(supply) networks.
Harms associated with distribution (supply) 
To examine the harms related to the distribution of MDMA, it is worth first 
making the general point that there are many misperceptions about the nature of 
the drug supply which make discussion of drug policy reform more difficult181, 182. 
Contrary to the popular perceptions of drug dealers lurking in dark alleyways or 
around school gates, many people who use MDMA report obtaining their drugs 
from friends and established contacts. This creates a risk of serious criminalisation, 
sometimes even imprisonment, for young people engaging in non-profit ‘social 
supply’ amongst peer groups or small-scale opportunistic dealing183. Such 
criminalisation can have devastating impacts on the prospects of young people, 
potentially far more harmful than occasional drug use184. If intended to deter 
use and protect health, the criminalisation of such low-level actors in the drug 
market is likely to be counterproductive. Not only is there no evidence to suggest 
that such enforcement meaningfully disrupts supply or reduces availability, but 
also the negative impact of a criminal record and associated stigma on personal 
relationships, employment, housing, or personal finance ironically may in fact 
increase the likelihood of an individual developing more problematic drug-using 
behaviours. The harms of criminalising young people who use drugs, who engage 
in ‘social supply’ to friends, or who are involved in the lower tiers of the drug 
supply are widely acknowledged. This recognition of the harmful consequences of 
the status quo has driven calls from health agenciesk and high-level voices across 
the UN system, including the World Health Organisation, the UN Office of the 
High Commissioner for Human Rights, the UN Office on Drugs and Crime, 
k These include the Royal Society for Public Health, the Royal College of Physicians, the 
government’s own ACMD, the American Public Health Association, the British Medical 
Journal, and the UK Faculty of Public Health.
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and three consecutive Secretary Generals, for alternatives to the punishment 
and incarceration of low-level drug offenders to be explored. What is clear is 
that we need to reform policy and law around MDMA to ensure that young 
people are not unfairly or disproportionately criminalised185. 
Drug dealing often attracts young people in situations of social vulnerability, 
which can further perpetuate cycles of exclusion if they are prosecuted186, 187, 188. 
Most recently, there has been growing concern amongst law enforcement agencies 
and child protection services about the growth of ‘county lines’ in England and 
Wales189, 190. A ‘county line’ is where an individual, or more frequently a group, 
establishes a telephone number (or an address) in an area outside of their 
normal locality to sell drugs – typically but not exclusively crack cocaine and 
heroin – directly to users at the street level. This usually involves an organised 
gang from an urban area expanding their operations by crossing one or more 
police force boundaries to more rural areas, setting up a secure base, and using 
drug ‘runners’ to conduct day-to-day dealing. Urban organised drug gangs are 
recruiting marginalised children and young people as drug ‘runners’ for these 
‘county lines’, whilst also establishing ‘secure bases’ in the homes of vulnerable 
(often young) people to force their co-operation with actual and threatened 
physical and sexual violence. Other grooming activities include paying children 
large sums of money or giving them drugs for their efforts, or ‘rewarding’ them 
with additional gang status and responsibility which effectively puts them at 
greater risk of intergang violence191. 
Whilst there is as yet little evidence of drugs distributed via county lines 
being sold in the NTE (unsurprising given that county lines focus on lucrative 
heroin and crack cocaine markets), one source has reported the recovery of 
MDMA from runners191. It has been acknowledged by parents, frontline 
staff, and child protection academics and practitioners that the children and 
young people in these situations should be treated as victims/survivors, not 
as criminals191. However, in reality, the prohibition system makes this hard 
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to guarantee when seeking to help and support the young victims/survivors 
of drug gangs. Conversely, the move to decriminalise simple possession and 
low-level dealing offences for all drugs – including MDMA – which we call 
for in this report would remove these and other young people entirely from 
their positioning as ‘criminals’, providing an opportunity to disrupt the cycle of 
exclusion that allows organised gangs to prey on them. 
The fear of ‘getting into trouble’ with the authorities is strong amongst 
members of marginalised communities (especially young people) who already 
receive disproportionate law enforcement attention relative to their actual 
involvement in drug markets192. In the failed attempt to ‘control’ drugs through 
the criminal justice system, drugs are understood through the prism of criminality, 
rather than that of public health. This is unacceptable given that the goals of 
drug policy should include the protection of vulnerable populations. Fears 
around legal consequences are apparent in some young people’s reluctance to 
contact emergency services if they or a friend experiences an adverse reaction to 
drugs. This means that young people who use drugs are over-policed and under-
protected. If young people do experience acute health issues in relation to their 
MDMA use, they are less likely to seek help as they may fear repercussions in 
relation to social dealing. They may also worry about potential media coverage of 
MDMA-related incidents and social supply. This is a justifiable fear, given that 
nearly every MDMA-related death is covered in the UK press98. This further 
discourages people from seeking medical help if they or their friends become 
ill or die following the ingestion of unregulated MDMA products. In a recent 
tragic case in the UK, a young female student who shared MDMA pills with 
her best friend, who subsequently died whilst out celebrating the end of term 
at university, was jailed for six months after being charged with possession 
with intent to supply a Class A drug193. Indeed, MDMA media reporting 
routinely includes articles on the prosecutions of the people – including partners, 
friends, or acquaintances – who supplied MDMA to someone who later died 
or experienced a medical emergency. In another widely reported UK case, the 
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19-year-old boyfriend of Faye Allen, a 17-year-old who passed away the first 
time she used the drug at the Warehouse Project in Manchester, was jailed for 
seven months for giving an MDMA pill to Faye which he had purchased from 
an unknown dealer on the premises194.
The harms associated with MDMA supply are felt by those caught up in 
a failing justice system, which often indiscriminately and disproportionately 
criminalises ‘dealing’, regardless of motive, intent, or even the extent of activity. 
The relevant comparison here is that no one is criminalised or imprisoned for 
buying an alcoholic drink for friends, despite the hugely negative effects of 
excessive alcohol use in the NTE on young people, local communities, and 
emergency services. Finally, although few people seek help for problematic 
MDMA use, MDMA may be but one illegal substance in a person’s polydrug 
repertoire which, in its totality, leads them to experience problems. Willingness 
to seek help for problematic drug use has been found to be lower amongst those 
who reside in countries with more punitive prohibition routines, leading some 
to argue that liberalising national drug policy will increase the propensity of 
people who take (currently) illegal drugs to utilise health services195.
As with ‘county lines’, the prohibition status quo has proven unable to 
respond adequately in an agile manner to the harms of emergent drug distribution 
systems. Here, it is crucial to acknowledge the growing role of the internet and, 
more recently, social media apps in the distribution of MDMA products196. 
There may be harm reduction benefits from the development of online markets, 
including the avoidance of direct contact with potentially unknown criminal 
dealers, and user rating systems on the darknet which may help act as a form 
of quality control197. However, online MDMA markets also pose specific kinds 
of risks in addition to the more common risks associated with purchasing from 
criminal markets. The internet has created an easily accessible supply route 
for tech-savvy young people who may not otherwise have access to street or 
social dealers of MDMA, and may increase MDMA availability for certain 
vulnerable populations. Of course, there are no age-verification mechanisms 
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when purchasing MDMA from the darknet. Key areas of continuity and change 
between MDMA markets of the 1990s and contemporary MDMA markets 
have been subject to recent scrutiny198. Contemporary MDMA markets are 
increasingly globalised with the emergence of industrialised production processes, 
intercontinental export, and anonymous and untraceable online drug purchasing 
through the darknet with cryptocurrencies199. The emergence of online markets 
in one respect reflects the ‘success’ of conventional supply-side enforcement, 
which has created risks for both buyers and sellers sufficient to incentivise the 
move online. However, this more objectively reflects the wider failure of the 
prohibitionist paradigm; markets are not being eradicated but simply being 
displaced from face-to-face transactions to a highly flexible online market that 
is effectively beyond the reach of enforcement. This creates some new risks 
but also some potential benefits from the user perspective (such as increased 
anonymity, reduced risk of arrest, avoidance of criminals, and quality control)200. 
These rapid and risky developments in MDMA markets demand novel solutions 
which challenge the outdated approach of total prohibition. Changes in MDMA 
distribution models, such as the use of the darknet and social media to obtain 
MDMA197, mean that any possible future alternative to prohibition must be 
prepared to deal with ‘real-world’ consumer practices. 
Figure 12.
Screenshot of the Silk Road, 
the former online 
darknet marketplace.
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Financial costs of retaining the prohibition status quo
As with any law, there are costs associated with enforcement, such as the cost of 
policing, courts and judicial procedures, imprisonment, etc. In terms of relative 
investment of enforcement resources, MDMA is not in the top tier of UK 
or EU priorities, unlike, for example, cocaine or heroin trafficking. Most law 
enforcement authorities take a fairly pragmatic approach. Indeed, compared 
with some other drugs, statistics suggest that MDMA-related offences make 
up only a small proportion of drug offencesl, 1. Data detailing the exact costs 
of enforcement measures for MDMA, in either money or expended time, are 
unavailable. However, according to recent UK Home Office data, 65% of ‘Ecstasy’ 
seizures in 2017/18 involved 10 or fewer doses, whilst only 10% involved over 
100 doses201, demonstrating that significant enforcement time, effort, and funding 
is being spent on targeting people who use MDMA or on social supply rather 
than organised crime groups. 
Another key cost associated with the prohibition of MDMA is the profits it 
provides to criminal markets. Prohibition seeks to deter illegal drug production 
and distribution by heightening the risks of prosecution and imprisonment. 
However, the low rates of capture and conviction of those operating in illegal 
drug markets1 suggest that the theoretical risk of prosecution has a minimal 
deterrent effect. Instead of deterring criminals, prohibition ensures that their 
profits remain high as their risks are passed on to consumers in the form of 
increased costs, combined with simple profiteering within a criminal monopoly 
l Data gathered by the EMCDDA indicate that MDMA was implicated in less than 3% of 
registered drug offences in the UK. This is 1% higher than the numbers for MDMA-re-
lated offences seen throughout the EU. In 2017 (the latest figures available), an estimated 
1.5  million drug law offences were reported in the EU. Most of these offences (79%) 
related to use or possession, totalling around 1.2 million offences, a 27% increase com-
pared with ten years ago. Drug use or possession offences involving cannabis continued 
to increase. The upward trend in offences for MDMA use or possession continued across 
the EU in 2017, although they still only account for 2% of use-related offences1. 
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with no competition from the legal economy. At the same time any opportunities 
for legitimate economic activity and tax revenue from the market are forgone. 
Lost benefits
Recreational use
Much research on MDMA use, as with most illegal drugs, has focused on harms, 
with little attention paid to potential benefits140, either objective or subjective. 
The effects experienced when taking MDMA include a well-documented sense 
of ‘openness’, euphoria, and closeness to others130, 202, 203. These are the highly 
sought-after effects that help account for the enduring popularity of MDMA. 
According to a large global web survey of people who use drugs, MDMA has 
the highest Net Pleasure Index (calculated by subtracting rating scores for 
negative effects experienced from the scores for positive effects) of all surveyed 
drugs204. Aside from pleasure, MDMA may have social functions that its users 
find valuable. For example, MDMA use may create a unique environment in 
which people can express and enjoy closeness in ways that are otherwise outside 
of their cultural norms. Researchers have long noted the sense of community 
and belonging experienced by young people in dance music scenes which they 
may not experience elsewhere205. One study has examined ways in which young 
men on MDMA are able to communicate, play, and experience their friendships 
in ways that are otherwise not consistent with social norms guiding masculine 
behaviour206. 
Clinical and therapeutic use
Before MDMA acquired its illegal status in the US in 1985, it was used by 
several dozen psychotherapists who believed it to be a valuable and effective tool 
to augment the psychotherapeutic process. George Greer, a psychotherapist who 
administered MDMA during this time, estimated that the combined clinical 
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experience in the US prior to the ban totalled more than 1,000 sessions207. 
However, the exact size of the medical following MDMA had commanded is 
impossible to determine and estimates vary considerablym. Anecdotal and case 
reports were published, but no controlled clinical trials were carried out before 
1985208, 209, 210. Case reports observed that MDMA produced strong positive 
results for a range of mental health conditions208, 211. Available accounts indicate 
that MDMA-supplemented psychotherapy was thought especially effective in 
couples’ therapy and for overcoming fear and anxiety, for example in the context 
of PTSDn. In 1985, the prohibition of MDMA in the US stopped large-scale 
studies from putting these uses on a firmer clinical foundation, although there 
is evidence that the ‘underground’ use of MDMA for psychotherapy did not 
entirely cease and that therapeutic use continued in some parts of Europe for 
some years following this, notably in Switzerland212, 213. 
Due to regulatory obstacles and the preference of conventional funding 
bodies to support research into the harms of controlled drugs more often than 
into their potential uses, research on MDMA’s therapeutic potential stalled 
for almost twenty years. While still contested by some214, MDMA is now 
experiencing a revival of appreciation for its emerging therapeutic properties, 
especially when administered in a controlled environment, with optimal set and 
setting using safe clinical research models and methods215. Phase 1 and Phase 
2 clinical trials have been conducted to test the potential benefits of MDMA-
assisted psychotherapy in the treatment of PTSD, with positive results. The latest 
Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored study, 
involving twenty-six individuals (veterans, firefighters, and police officers) with 
PTSD who were randomly assigned either 30 mg, 75 mg, or 120 mg of MDMA 
together with psychotherapy, reported that 68% of the participants assigned 
m The 2018 MAPS Investigators Brochure refers to 500,000 doses of MDMA having been 
administered in psychotherapy sessions prior to its scheduling.
n See Neil Wood’s testimonial on the relationship between MDMA and PTSD at the end 
of this report.
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the higher doses no longer qualified for a diagnosis of PTSD one month after 
their second MDMA-assisted psychotherapy session, while the same was true 
for only 29% of the group assigned the lower dose. One year later, 67% of all 
participants no longer qualified for a diagnosis of PTSD, and all of those that 
retained their diagnosis experienced a reduction in symptoms216. Phase 3 trials 
are now underway following the Food and Drug Administration’s approval and 
designation of MDMA as a ‘breakthrough therapy’ for PTSD217.
MDMA is unlikely to be a suitable drug for regular use in the way in which 
selective serotonin reuptake inhibitors are used to treat clinical depression. 
However, it is hoped (with increasing evidential support) that lasting benefits 
can result from a small number of psychotherapy sessions (two to five, typically)75 
in which the drug is administered to the client218. So far, MDMA-assisted 
psychotherapy appears to be remarkably effective in easing or resolving PTSD 
in individuals who had not been helped by mainstream treatment options214, 
219, 220, 221, 222, 223. Research is also underway to determine whether MDMA-
assisted psychotherapy can help autistic adults with social anxiety23, 224, patients 
with anxiety relating to a life-threatening illness, and people with alcoholism. 
The range of problems for which MDMA could provide therapeutic benefits 
is yet to be determined, but new insights into its mechanism suggest that 
appropriate indications for MDMA-assisted psychotherapy could be diverse. 
The drug may increase the efficacy of psychotherapy by strengthening trust in the 
therapeutic alliance225, increasing self-compassion and reducing self-criticism226, 
and making it easier to approach and discuss traumatic memories without being 
overwhelmed227. Increases in patients’ openness and decreases in neuroticism 
may help the benefits last228.
In 2012, the Beckley / Imperial Research Programme carried out the first 
brain imaging study on individuals under the influence of MDMA, as part of the 
Channel 4 programme Drugs Live: The Ecstasy Trial, which was presented by Jon 
Snow and was viewed by over 2 million people. This was the first detailed study 
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to map the neural underpinnings of MDMA’s effects, and to explain why it is 
so valuable for psychotherapy. Following on from insights gained through work 
with PTSD patients in psychotherapy, this study explored the idea that MDMA 
makes people’s worst memories more bearable. It also offered thoughts on the 
neurobiological mechanisms that may underlie this characteristic. Favourite 
memories were experienced as more vivid, emotionally intense and positive after 
MDMA as compared to placebo, and worst memories were rated as less negative. 
This manifested in the brain as decreased activity in the amygdala (involved in fear 
processing), the hippocampus (memory processing), and visual and somatosensory 
areas227,229. Taken together, these results demonstrate the unique value of MDMA 
in psychotherapy as a tool to facilitate the recall of traumatic memories.
While largely ineffective at tackling the recreational demand for MDMA, the 
international drug control regime has profoundly undermined the development 
of MDMA for therapeutic use, confining use to a few underground therapists212. 
In the UK for example, MDMA is listed in Schedule 1 of the Misuse of Drugs 
Regulations (MDR) 2001, imposing challenging financial and bureaucratic 
obstacles to preclinical and clinical research230. One experienced researcher 
estimates that research with a Schedule 1 compound takes several years to get 
approved and can ultimately cost ten times as much as the equivalent research 
with uncontrolled drugs such as alcohol231. Despite these restrictions, a new 
wave of interest and research into therapeutic uses of MDMA is now underway. 
Figure 13.
 A MAPS MDMA 
therapy session. 
Source: 
MAPS
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In Chapter Three, in detailing our roadmap to regulation for MDMA, we call 
for the rescheduling of MDMA to allow scientists and medics to explore its 
therapeutic potential, notably in the field of mental health, which is of growing 
concern to many communities and governments.
Harm reduction under prohibition
Having demonstrated how various harms relating to MDMA use are directly 
related to, or exacerbated by, the current prohibition regime, it is now necessary to 
consider how people who currently use MDMA mitigate potential harms before, 
during, and after their ‘session’. Whilst there is a long and proud history of harm 
reduction amongst MDMA users, this is largely ignored by mainstream drug 
researchers. Much research focuses exclusively on the negative aspects of MDMA 
use whilst ignoring the more positive aspects reported by users ‘on the ground’, 
including lay harm reduction strategies around MDMA use and the efficacy (or 
otherwise) of harm reduction interventions by concerned parties such as outreach 
drug services. Such strategies and advice are culturally transmitted among peers, 
including through the internet on drug user forums, and some are also promoted 
by interested drug workers and clinicians, organisations, friends, and dealers. 
Both lay and expert harm reduction practices and interventions are, in many 
cases, necessitated by the prohibitionist regime at the same time as being severely 
curtailed by it. The first difficulty for MDMA users is where and from whom 
to purchase the drug. Buying from trusted local dealers or friends who rely on 
reputation and customer loyalty may be a safer option than buying from an 
unknown, unaccountable dealer at a festival, at a nightclub, or on the street11. 
Some darknet markets provide consumer feedback scores for vendors, which 
allows for the development of a reputation akin to legitimate sites like eBay. This 
feature may make darknet purchases less risky than buying from unknown street 
dealers, although some have questioned the safety of this development in the 
MDMA market197.
Figure 14.
MDMA crystal on The Loop’s bruker 
alpha FTIR testing surface. 
Source: 
The Loop
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Some users test their purchase using simple qualitative chemical home-
testing kits, which indicate the presence of MDMA or some other drugs 
with a colour change232. These kits have the potential to help users avoid some 
fake or adulterated products, but if their limitations are not recognised (e.g., 
confirmation of the presence of MDMA does not confirm the absence of a 
dangerous adulterant, and gives little indication of potency), users may gain 
a false sense of security233. Access to more technologically sophisticated drug 
testing services is legally constrained in the UK, although the Home Office has 
recently shown a willingness to step back from its previous objections234. The 
Loop235 are pioneers in combining on-site drug testing with harm reduction 
services in the UK, operating with the cooperation of law enforcement, although 
their testing services are currently only available to a tiny minority of people who 
use drugs attending specific dance events and festivals, and in a small number 
of city centre locations. Such services have a longer history of effective, albeit 
limited deployment in Spain, Austria, Switzerland, and the Netherlands; and are 
now emerging in Australia, Canada, Latin America, and elsewhere in Europe. 
The internet provides a way for adulteration warnings and dose information 
about specific MDMA tablets to be shared (e.g., www.pillreports.net), although 
the utility of this service is limited by the ease with which pill designs recognised 
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as high quality can be copied. In the Netherlands, the Drugs Information and 
Monitoring System (DIMS) has provided consumers with the service of having 
drugs analysed for free since 1992236. In the UK, the Welsh Emerging Drugs 
and Identification of Novel Substances (WEDINOS)o and The Loop perform 
similar functions. 
MDMA dose control still represents a key aspect of harm reduction. Scales 
with the necessary sensitivity (0.001 g) utilised for single doses of MDMA 
powder are relatively affordable as an alternative to ‘eyeballing’ doses. Harm 
reduction advice, to start with half or a quarter of a pill and wait for the results, 
has been proposed to minimise the risks of excessive doses and adulteration237. 
However, in the context of high-profile deaths of young people, this remains 
a highly sensitive and politicised area which suffers from sensationalist press 
reporting. For example, when suggesting that people who use MDMA should 
stick to taking pills in halves, Professor Valerie Curran was vilified in the British 
tabloid press for allegedly ‘encouraging’ drug use238. This has historically been a 
frequent challenge for more pragmatic drug harm reduction efforts, which still 
have to negotiate the simplistic ‘just say no’ and ‘zero tolerance’ messaging that 
continues to dominate much political discourse. 
Using harm reduction strategies, current users can exert a degree of control 
over their MDMA experience and risk exposure before, during, and after 
a given ‘session’ through careful purchasing, planning of the usage scenario, 
responsible dosing and self-care, and aftercare. However, some people who use 
MDMA depend upon word-of-mouth information and peer advice, which 
may be inaccurate. Targeted harm reduction programmes informed by scientific 
evidence and ‘real-world’ practices, and ideally co-developed with young people 
o The Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) proj-
ect, an initiative receiving support from Public Health Wales, has analysed more than 
7,000 samples from across the UK in the last six years. The service currently holds an 
exemption from the Home Office allowing it to possess controlled drugs – an exemption 
plausibly maintained because of the service’s relative obscurity.
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who use MDMA, remain inadequate and under-resourced, not least due to the 
austerity-driven cuts to public health and education budgets, vital alcohol and 
drug services, and youth services in the UK.
Just as the pressures of prohibition lead to a needlessly high-risk product, 
they may also lead to particularly unsafe contexts for use. The pressures on 
users to avoid detection and on nightclubs and festivals to demonstrate zero 
tolerance appear to create conditions that are not conducive to responsible use. 
For example, nightclubs may utilise intensive searches or even sniffer dogs to 
deter drug use, which may unintentionally encourage users to take all their drugs 
at once before entering239. Australian research on the use of drug detection dogs 
at outdoor music festivals, a measure introduced in response to a spate of drug-
related deaths at such events, points to their failure to deter festival-goers from 
smuggling drugs into festivals, with a mere 4% of survey respondents indicating 
that they would change their behaviour if they knew detection dogs were going 
to be at festival entry points240. Australia, the US, Canada, and indeed the UK 
make extensive use of police sniffer dogs at popular dance events, despite long-
standing weak evidence as to their deterrent effect241 and associated emergencies 
(including fatalities) resulting from panicked ingestion. Recent responses to 
drug-related deaths at EDM festivals in Vietnam and Australia have included 
local leaders talking ‘tough on drugs’ and banning such events altogether242, 243.
The evidence from alcohol research shows that when club-goers have an 
incentive to get intoxicated before arriving (e.g., by on-premise alcohol prices), 
they drink more in total and are more likely to be involved in risky behaviours244. 
MDMA users may act similarly by starting their consumption before going 
into the club for fear of being searched, meaning that searches have a harm-
exacerbating effect240. Users may consume too much, too quickly, inhibiting 
well-evidenced harm-reducing strategies such as starting with half a pill and 
waiting for an effect. Additionally, they may then purchase drugs from strangers 
inside the club who, in comparison to dealers known to the user, are likely to 
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offer a dangerously unpredictable product. Snatching covert opportunities to 
consume MDMA is not consistent with careful measurement, or with looking 
out for one’s friends by maintaining awareness of what and how much they are 
taking. Escalating pressures on users (and banning dance events) may displace 
MDMA consumption to less regulated private spaces, which are thought to be 
a risk factor for acute drug harms and deaths239, or into completely unlicensed 
events (unlawful ‘free parties’ and raves) where recent MDMA-related deaths 
have also occurred245, 246. 
In this chapter we have outlined the harms associated with MDMA 
production, distribution (supply), and use. We have reviewed the evidence in 
relation to acute harms from MDMA use, as well as sub-acute and chronic harms, 
and have demonstrated how the illicit production and distribution (supply) of 
MDMA entails a range of harms specific to the current policy environment 
in which they arise. Prohibition needlessly exacerbates the risk of medical 
emergencies and death amongst people who use MDMA. Criminalising users 
hinders the dissemination of important information and advice about safer 
forms of use that significantly reduce potential acute, sub-acute, and (to a lesser 
extent) chronic harms related to MDMA, not to mention the devastating impact 
a custodial sentence and criminal record can have on a person’s life.
Most MDMA-related harms emerge from the very drug laws which are 
meant to protect public health, safeguard vulnerable populations, and reduce 
drug-related harm. Harm reduction initiatives such as drug safety testing services 
are crucial as they help to mitigate the most negative intended and unintended 
consequences of prohibitionist policies247. Indeed, much drug policy change 
advocacy rests on evidence from harm reduction research and practice, as is 
apparent throughout this report. As we move towards the creation of a strictly 
regulated legal MDMA market, harm reduction will play an increasingly visible 
role in MDMA user choices.
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In a post-prohibition context where users have access to safer legal MDMA 
products, harm reduction initiatives, such as the supply of free drinking water 
in nightclubs and at festivals, would continue, whilst others, such as drug safety 
testing for adulterants, would no longer be needed. For the policy changes we 
advocate in this roadmap to regulation to work, MDMA users must be ‘on board’ 
with measures to reduce potential risks of drug consumption. Fortunately, the 
appetite for safer drug use practices is already apparent, with 99% of people who 
used MDMA in England and Wales in 2019 stating that it is not advisable to 
take the substance frequently45. That figure supports a view of users as rational 
agents who attempt to balance the risks and rewards of drug use in the broader 
context of their lives, rather than ‘out of control hedonists’, who, whether 
purposely or unwittingly, put themselves and society at risk248. Club drug users 
tend to want to have as much fun as possible as safely as possible249. Recent 
successful attempts to engage people who use drugs at music festivals with harm 
reduction advice following drug safety testing (e.g., The Loop) further supports 
this view250. Overall, we envisage the proposed two-phase drug policy reform 
process – decriminalisation of possession and low-level dealing followed by legal 
regulation – as further supporting and empowering people who use drugs to 
practice harm reduction and responsible use.
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3 . 1 The goals of policy reform
It is important to explore what a fully realised, culturally integrated system of 
MDMA regulation might look like, whilst also considering the incremental 
steps needed to make it a reality. Minimising harm during the transition should 
be the priority, rather than taking the shortest route towards the end goal. The 
proposed model includes a phased introduction of policy reform, beginning 
with rescheduling MDMA and decriminalising possession, which would 
reduce some of the harms associated with current drug policy without requiring 
significant legislative and administrative restructuring. The second phase of 
policy reform details the development of a strictly regulated legal MDMA 
market. The actions in each phase would be carefully monitored and evaluated 
to ensure that they are fulfilling the specific goals of reform. We need to be very 
clear about these goals to ensure that the overarching principles of the reform 
process are not lost. These principles are premised upon the conviction that 
we can move towards a social and political engagement with drugs driven by 
public health promotion and harm reduction, evidence-informed policy and 
practice, human rights, social justice, and participatory democracy. Bearing 
these principles in mind, the foregoing considerations suggest that the key goals, 
related actions for MDMA drug policy reform, and the phases of reform they 
align with are as follows:
 
Overarching goals
 • Minimise health risks related to MDMA use.
 • Minimise social, environmental, and health harms related to MDMA 
markets (production and distribution).
Chapter Three
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 • Minimise the social and economic costs of MDMA-related policy and its 
enforcement.
 • Harness the therapeutic potential of MDMA.
Specific goals
 • Minimise MDMA use by underage and other vulnerable populations.
 • Encourage safer modes and patterns of consumption.
 • Ensure the quality and consistency of MDMA products on the market.
 • Decrease the income fuelling the criminal market.
 • Introduce cost-effective harm reduction methods.
 • Ensure optimal opportunities for the scientific study (and application) of 
MDMA’s therapeutic potential.
Proposed model for reform
The key actions aligned with each phase are outlined below: 
Phase 1: Actions
 • Reschedule MDMA from a Schedule 1 drug to a Schedule 2 drug under 
the Misuse of Drugs Regulations (MDR) 2001 in the UK. Equivalent 
rescheduling could take place in other jurisdictions and under UN treaties.
 • Decriminalise MDMA possession and low-level supply (as part of broader 
decriminalisation).
 • Roll out drug testing and other relevant harm reduction services.
Phase 2: Actions
 • Build a strictly regulated legal market for MDMA products.
 • Establish a new public authority body charged with overseeing, monitoring, 
and evaluating the implementation of regulation.
3 . 2
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 • Ensure that public health promotion and harm reduction, evidence-informed 
policy and practice, human rights, social justice, and participatory democracy 
inform both Phase 1 and Phase 2.
Phase 1
Rescheduling MDMA
The Misuse of Drugs Regulations (MDR) 2001 is the UK legislation that 
determines who can lawfully produce, supply, and possess controlled drugs, and 
the conditions under which they are authorised to do so. MDMA is categorised 
in Schedule 1 in the MDR, and in equivalent positions in other jurisdictions’ 
analogous legislation (e.g., Schedule 1 of the US Controlled Substances Act), 
as well as in international law (e.g., Schedule 1 of the UN’s Convention on 
Psychotropic Substances). 
Schedule 1 drugs are deemed to have minimal or no therapeutic value 
and are subject to the highest levels of control. MDMA is listed alongside 
LSD, psilocybin, and cannabis in Schedule 1; whereas heroin, cocaine, and 
amphetamines, which have established medical uses despite well-known risks 
associated with non-medical use, are listed in Schedule 2. Although Schedule 
1 drugs may be used for the purposes of research in the UK, a Home Office 
licence is required. Such licences are difficult to obtain, often taking in excess 
of a year of substantial bureaucracy, costing more than many research budgets 
can accommodate, and only being available for a limited period (usually 
one year). Since Schedule 1 drugs for research purposes must be sourced 
from legitimate organisations, these organisations, their production sites, 
and their distributors must also meet the onerous licensing requirements 
imposed by the Home Office. As such, the total costs and bureaucratic 
demands associated with such research are further increased, and national 
funding agencies (e.g., the National Institute for Health Research and the 
3 . 3
3 . 3 . 1
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Medical Research Council) have rarely funded clinical trials with Schedule 
1 drugs. Placement in Schedule 1 of the MDR is arguably undesirable for 
any compound given that doing so effectively amounts to a near-prohibition 
on research. To the extent that policies and practices guided by and based on 
robust scientific evidence are desirable, restrictions on research should not 
be so onerous as to exclude scientists working at legitimate institutions from 
furthering our understanding. 
The placement of MDMA in Schedule 1 is also undesirable when considering 
its position as one of the world’s most popular illicit recreational drugs. The 
more widely taken up any practice is, the more desirable it is to have a fully 
developed understanding of its health impacts. Moving MDMA into Schedule 
2 will reduce the political, bureaucratic, and cost barriers to scientific research 
associated with a Schedule 1 status. As almost all UK universities can possess 
and conduct research on Schedule 2 compounds without the need for additional 
expenses or licences, the wider community of scientists who seek to investigate 
MDMA’s mechanisms of action and effects will be able to do so unimpeded. This 
will facilitate further research into MDMA’s therapeutic uses and non-medical 
uses, allowing us to improve our understanding of its effects on the body, and 
deliver insights that can inform the shape and pace of policy reform. 
Rescheduling will also facilitate access to MDMA-assisted psychotherapy 
for specific indications, once clinical trials have demonstrated treatment 
efficacy. To protect the interests and safety of patients, some of whom may 
be vulnerable, therapeutic use of MDMA would only be available in the 
context of MDMA-assisted psychotherapy delivered by qualified and licensed 
practitioners, following a doctor’s referral. This therapy would be provided 
by mental health professionals who have obtained specialised training in 
psychedelic-assisted therapy and a licence to administer MDMA for specific 
indications. In the context of increasing rates of mental health diagnoses in the 
UK and beyond, promoting the training of MDMA-assisted psychotherapy 
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practitioners will allow us to capture for society the heretofore lost therapeutic 
benefits of MDMA.
The UN process for transferring a psychoactive substance from one 
Schedule to another involves a critical review by the World Health Organisation 
Expert Committee on Drug Dependence, which is then voted on by the UN 
International Narcotics Control Board. In practice this is a more fraught process 
than the domestic one. The mechanics of rescheduling MDMA in the UK from 
Schedule 1 to the less restrictive Schedule 2 are comparatively straightforward 
and can be done, for example, by the Home Secretary without recourse to 
bringing forward primary legislation, but instead via a statutory instrument 
following consultation with the ACMD. This procedure has recently been 
witnessed in relation to medicinal cannabis in the UK. If MDMA proves to be 
a safe and effective treatment for PTSD in the MAPS Phase 3 trials currently 
running in the US, Canada, and Israel, this will necessitate its rescheduling. 
However, we suggest that waiting for the completion of these trials will waste 
several more years, during which important research will be hindered by the 
needless bureaucracy and prohibitively high costs of securing Schedule 1 research 
licences.
As it stands, potential concerns around moving MDMA into Schedule 
2 remain marginal ones. By itself, rescheduling has no bearing on the matter 
of recreational use, meaning that those in Parliament who undertake the 
rescheduling can position themselves as supporting scientific research without 
risking being perceived as ‘soft on drugs’. There is little-to-no risk of diversion 
to the recreational market: were MDMA to be placed into Schedule 2, it would 
be subject to the same strict restrictions and controls that are sufficient for 
significantly more harmful, more dependency-forming drugs such as cocaine 
and morphine. There are no reports that diversion of cocaine or morphine from 
clinical or research settings is a significant cause for concern. Moreover, there 
are no grounds for supposing that there would be such a diversion problem with 
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MDMA, particularly considering the low reported rates of MDMA dependency, 
and the fact that current clinical indications for MDMA involve infrequent use 
in the presence of a therapist, rather than the use of a take-home prescription.
Decriminalising possession of MDMA for personal use
The first phase of the roadmap to regulation for MDMA must include 
decriminalising the possession of all illegal drugs. While the term decriminalisation 
is not formally defined, it is generally understood that under a decriminalisation 
approach, possession of small amounts of controlled drugs would remain an 
offence but would be a civil or administrative offence rather than a criminal one. 
It would be more akin to a speeding offence, no longer involving a criminal record 
or threat of a custodial sentence. As such it can be seen more usefully as ending 
the criminalisation of people who use drugs rather than decriminalising the drugs 
themselves. Following decriminalisation, people caught with a limited amount 
of MDMA for personal use would have the drugs confiscated and could still be 
fined or subject to some other sanction or intervention such as a requirement 
to attend a drug education session (rather like the speed awareness courses for 
those caught speeding in some countries), or a treatment assessment. Elsewhere, 
notably in Portugal, there have been changes to penalty regimes which focus 
more on civil penalties and drug treatment referrals for those understood to be 
experiencing problems with their drug use251, 252. In the UK we are gradually 
seeing the establishment of local drug offence diversion schemes implemented 
by local police authorities, creating a de facto system similar to the model in 
Portugal. Such schemes are a form of harm reduction specific to the pernicious 
effects of disproportionate police attention and unwarranted involvement in 
the criminal justice system253, especially for young black, Asian, and minority 
ethnic (BAME) people living in urban locales254. In the UK, BAME people are 
subjected to ‘stop and search’ powers on suspicion of drug possession at almost 
nine times the rate of white people, despite lower ‘find’ rates from searches of 
BAME people, as well as lower self-reported rates of drug use254. 
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As well as being inherently unjust, disproportionality and racial bias 
contribute to weakened trust and confidence in the police among ethnic 
minority communities, compromising operational effectiveness in all aspects of 
community policing. Whether decriminalisation is de jure in nature, established 
through amendments to the UK’s MDA 1971, or de facto, by police forces 
making operational decisions to deprioritise or deal differently with minor drug 
possession offences, decriminalisation would free the criminal justice system 
from a significant burden. Police resources could be re-diverted to other priorities 
such as violent crime, and there would be a pronounced reduction in the need 
for stop-searches, which are justified by suspicion of drug possession in as much 
Figure 15.
Source: 
[Release.org.uk]
The Colour 
of Injustice.
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as 82% of cases in some police forces255. This point is one reason why we call for 
decriminalising the possession of all illegal drugs, rather than of MDMA alone; 
the decriminalisation of MDMA possession alone would not entail the removal 
of ‘suspicion of drug possession’ as a basis for stop and search in its entirety and 
so would not tackle the disproportionality and racial bias of drug policing.
Fears that ‘softening’ the stance towards drugs such as MDMA would result in 
a rapid increase in prevalence of use, and therefore harms, are understandable, but 
are not borne out by existing policy evaluation evidence256. Careful consideration 
of the evidence from Portugal has found that their move from criminal to civil 
penalties has not led to major increases in drug use prevalence rates257, 258. There 
have, however, been reductions in drug-related harms, problematic drug use, 
and criminal justice overcrowding. The low levels of problematic usage patterns 
among MDMA users and concomitant low levels of entry into treatment related 
to its use mean that drug treatment orders are of limited relevance, and that 
targeted drug education interventions may be more appropriate. In sum, a shift 
from criminal to civil penalties for MDMA possession and low-level supply 
offences will ensure that disproportionate consequences for relatively benign 
infractions of the law do not impact the liberties and lifetime opportunities 
afforded to users. In the longer term it is reasonable to argue that there should 
be neither criminal nor civil penalties for people who use drugs, including 
MDMA users259. This aligns with the values, goals, and actions outlined at the 
beginning of this chapter. 
Calls for the decriminalisation of drug possession for personal use can no 
longer be considered a fringe view. Drug decriminalisation would remove criminal 
penalties for drug use and possession, and low-level drug sales which correspond 
to ‘social dealing’. The UK government’s own ACMD, the British Medical 
Association, the Royal Society for Public Health, the Royal College of Physicians, 
and three consecutive UN Secretary Generals alongside multiple UN agencies 
have all called for the decriminalisation of drug possession. Indeed, in 2018 the 
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UN Chief Executives Board – representing 31 UN agencies – unanimously 
endorsed the decriminalisation of drug possession, calling for member states 
to ‘promote alternatives to conviction and punishment in appropriate cases, 
including the decriminalization of drug possession for personal use’260. The UN 
Chief Executives Board statement also positions drug policy clearly within public 
health, human rights, and sustainable development agendas, which again aligns 
with the values, goals, and actions outlined at the beginning of this chapter. 
As well as improving social justice outcomes for users of MDMA, 
decriminalisation will serve to improve health outcomes by removing barriers 
to harm reduction and health services, and increase willingness to access 
them amongst vulnerable populations who might have previously feared legal 
complications. Those on probation, for example, can access treatment support 
without having to first admit to an offence. Currently, UK drug safety checking 
services like those offered by The Loop operate in a legal grey area, neither 
explicitly sanctioned nor prohibited by the government, despite evidence 
that such services reduce harms to those with whom they interact261. It is 
worth noting that drug safety checking represents a form of de facto localised 
decriminalisation as it requires police non-enforcement of drug possession 
laws in order to function. Implementation of such services remains challenging, 
requiring co-ordination from a variety of stakeholders who are often uneasy, 
especially considering legislation that suggests that knowingly allowing drug-
related activity on one’s premises can be an offencea.
To reap the full benefits that could be derived from decriminalisation, it is 
appropriate that criminal penalties are removed for possession of any drug, and 
not solely MDMA. The disproportionate and biased use of stop-searches under 
a Under the MDA 1971, if the manager of a premises knowingly permits or suffers the pro-
duction or supply of drugs or the smoking of cannabis on his premises then s/he is liable 
to criminal prosecution. The maximum penalty depends on the class of drug involved, e.g., 
permitting the supply of MDMA on your premises could result in up to 14 years in prison 
and/or a fine.
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Section 23 of the MDA will not decrease if only one drug is decriminalised. 
Likewise, in the absence of a pragmatic, portable means of reliably distinguishing 
the identity of chemical compounds, the decriminalisation of one illicit white 
powder among many will not allow police to reallocate their resources effectively. 
Drug users intercepted by the police would likely claim that they were in 
possession of MDMA, and consequently the police would continue to open 
case files and send suspect samples for testing. The decrease in the stigma 
associated with problematic drug use and the increased uptake of drug treatment/
recovery services, which have been witnessed in Portugal, depend on wholesale 
decriminalisation. Decriminalising possession of MDMA alone, but not the 
possession of other drugs (such as heroin), may in fact feed into a narrative 
which marginalises users of other drugs, making them reluctant to access support. 
Likewise, the widespread practice of polydrug use calls for the implementation of 
wholesale decriminalisation so that the harm reduction benefits of drug testing 
services to be maximised.
Decriminalising people who use drugs, whilst a hugely important and positive 
step, would not significantly impact the illegal market itself. The production, 
transit, and supply of drugs remain prohibited under a decriminalisation model 
and therefore controlled by the same criminal entrepreneurs as before. The 
comprehensive rolling out of drug safety checking that could more easily occur 
under national or localised decriminalisation would go some way towards 
reducing the harms associated with unregulated MDMA products. However, 
the only way to ensure product reliability and improve safety would be to create 
a strictly regulated legal market for MDMA. 
Phase 2: Building a strict state-regulated legal market  
for MDMA
A key aim of a state-regulated legal MDMA market for adults is to establish 
mechanisms to ensure the standardisation of MDMA products and the safety of 
3 . 4
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the public, semi-public, and private environments in which they are consumed. In 
this section we outline Phase 2 of Roadmaps to Regulation: MDMA in more detail, 
highlighting how the careful establishment of such a market would meet the goals 
of drug policy reform, significantly reducing harms and regaining lost benefits 
for all stakeholders. We recognise that the regulation of MDMA is an emotive 
and contentious issue involving normative and ethical considerations as well as 
‘objective’ scientific evidence. Accordingly, we suggest that space should be made in 
any programme of drug policy reform for broader democratic participation in drug 
policy-making practices262, and a better understanding of the relationship between 
(contested) evidence, engagement, and participation (notably of drug users) in the 
making of drug policies263, 264, 265. A participatory process of this kind would ensure 
that lay public opinions – often excluded from policy-making processes – would 
be incorporated, and so help address public concerns, hopes and fears266, 267. 
The suggested model for the regulated supply of MDMA is designed to 
discourage potentially harmful patterns of use, including bingeing, polydrug use268, 
269, use in ‘high-risk environments’39, 40, and use by those under 18 years of age. 
Regulations around MDMA product accessibility would be vigorously enforced. 
A regulatory framework enforced by the police, customs officers, environmental 
health professionals, health and safety officers, and trading standards officers 
would define what MDMA preparations would be available, who could access 
them, and when and where they could be purchased. Accessibility for those who 
meet the purchase criteria (e.g., age, registered user with an available quota) 
would not be so onerous as to encourage the perpetuation of, or displacement 
to, illegal markets – although it is acknowledged that there is a balance to be 
struck between these sometimes conflicting objectives.
Currently, people who use MDMA go to their friends and peers, known 
or unknown dealers, or the darknet to source MDMA products199. As outlined 
in this report, the illegal MDMA market entails few or no safety checks on 
either products or their users. Concentrating MDMA product distribution in 
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specific outlets, licensed for a sole purpose with stringent regulatory systems 
in place, increases safety and minimises risk. This conclusion and our related 
recommendations are in keeping with the outcomes of recent attempts to 
evaluate the relative merits of different drug policy options using multi-criteria 
decision analysis (MCDA). MCDA is a tool employed in order to distil complex 
drug policy concerns into ‘a set of simpler judgements that lead to consensus 
about the results’270. The MCDA model sets out a series of concerns that drug 
policy should address, followed by policy options to compare (total prohibition, 
prohibition with decriminalised use, legal but strictly regulated, and a legal free 
market), and then assesses how these various policy options address concerns 
for a given drug, attempting to weight the relative importance of different 
concerns and allowing for trade-offs where necessary. Policy criteria include 
the reduction of harm to the user and to others (health), the improvement of 
education about drugs (social), the supporting of international development and 
security (political), the protection of children and young people (public), the 
criminalisation of users (crime), and the generation of tax revenue and reduction 
of public financial costs (economic)266.
Following an MCDA model to formulate and appraise drug policy on 27 
criteria in relation to alcohol and cannabis, respectively, 17 drug experts and two 
facilitators arrived at the conclusion that, of the four broad regulatory regimes 
(total prohibition, decriminalisation, state control, and free market), a state-
regulated legal access market provided the best overall outcomes in terms of minimised 
harms and maximised benefits. Nuances in the preferred regulatory regime emerged 
which reflect the differing harm profiles and associated behaviours relating to 
alcohol as compared to cannabis, with stricter controls on ‘legal access regimes’ 
for alcohol regarded as more important since its consumption produces greater 
(health) harms to self and others, than cannabis. In a sense it is these drug-
specific nuances, as they relate to MDMA, that we deal with in this report. 
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The MCDA model is but one emergent tool with which to progress towards 
better drug policy formulation. To reiterate, there would be no ‘blind’ rush to 
reform, uninformed by the evidence base, but instead a careful iteration of 
research–reform–research8. To account for unintended consequences, each 
phase of reform on the roadmap to regulation would be carefully evaluated 
via the production of high-quality research data, participatory democratic 
debate amongst key stakeholders (including people who use drugs), and expert 
judgements as to whether stated goals were being achieved by the actions 
relating to each phase. If, for example, the suggested model for MDMA 
product distribution by licensed vendors were to result in unintended harmful 
consequences for any stakeholder, the reform would be revisited and potentially 
revised. Models of good governance and democratic participation practices in 
relation to drug policy could be drawn upon to ensure the minimisation of harm 
to all involved271. With these caveats in mind, we now turn to the specificities of 
MDMA production, distribution, and use as envisaged in Phase 2.
Regulating production
A principal harm to users associated with illegal production and supply is 
the variability of products sold as MDMA. A regulated market with licensed 
producers operating within enforced standards of product safety and quality and 
producing MDMA products labelled with clear indications of dosage, potential 
adverse effects, and contraindications would go a long way towards mitigating 
these harms. Contracts for licensed producers would be put out to tender by 
the state, with strict controls and oversight of production and distribution 
implemented. The state would incur the costs of establishing and running a new 
regulatory agency to oversee the administration of the legal MDMA market. 
This agency would be responsible for the granting of production licences to 
a limited number of chemical manufacturing companies; monitoring and 
enforcing compliance with health, safety, and trading standards; and tracking 
the distribution of the product to licensed MDMA outlets. The widespread use 
3 . 4 . 1
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of accurate traceability technology, such as unit-dose packing (with barcodes), 
would add to overheads shared between producers and distributors (licensed 
vendors). These are necessary measures to help avert the prospect of legally 
produced MDMA products being diverted to a parallel illegal market, and are 
already apparent within well-established markets for high net-worth products 
(e.g., pharmaceuticals). The implementation of Phase 2 would involve no net cost 
to the state as costs would be met through licensing fees and taxes on vendors 
and MDMA products. The state would benefit from tax revenues from legitimate 
businesses operating where only criminals once did, as well as from a decrease in 
health care costs associated with adverse events (e.g., through lower admissions 
to accident and emergency departments). Licit producers would benefit from a 
legal business opportunity, whilst bearing compliance and administrative costs. 
A developing legal market would affect illegal producers, some of whom 
may turn to other (potentially more damaging) drug markets, such as those in 
NPS. However, with a forecast reduction in illegal MDMA-related activity, we 
would witness a decrease in related costs to the police and criminal justice system, 
especially if decriminalisation were extended to all drugsb. With the introduction 
of environmental controls to the production process, all stakeholders, most 
notably producer countries and countries where precursors and pre-precursors 
are made, would benefit from reduced ecological damage. Contextual factors, 
which would determine the impact of production regulations, include licence 
costs and requirements, monitoring (e.g., traceability measures), enforcement 
costs and enforcement spread (e.g., the number of trading standards officers), the 
level at which taxation is set, and the extent to which licit supply satisfies demand.
b It would be useful to produce a cost–benefit analysis of the creation of a legally regulated 
market for MDMA akin to the previous Institute of Social and Economic Research and 
Beckley Foundation report, Licensing and Regulation of the Cannabis Market in En-
gland and Wales: Towards a Cost-Benefit Analysis.
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Regulating  distribution (supply)
The supply of MDMA under the current prohibitionist framework is in the hands 
of profit-maximising criminal organisations. In addition to limiting society’s 
ability to control who has access to the product and how much they know about 
it, this can lead to a situation where MDMA is sold alongside other – often more 
harmful – drugs, encouraging (uninformed) consumption among adults and young 
people alike. Moreover, there can be additional adulteration of the substance at 
the supply stage (notably for MDMA powders). This all points to the need for 
a properly regulated distribution system (supply) rather than the unregulated 
‘free-for-all’ which currently exists, as detailed throughout this report. Within a 
strictly regulated legal market, there are many options for applying controls to the 
accessibility of MDMA, as well as providing opportunities for promoting safer use. 
MDMA product outlets: Licensed vendors (pharmacy model)
In order to be able to compete and ultimately supersede long-established illegal 
MDMA markets, a legal market regulated by the state would have to ensure 
that MDMA is made available to consumers on terms that are acceptable to 
all parties concerned.  We propose a specialist pharmacist retail model in the 
first instance as a way of meeting these demands272.  Pharmacies are a suitable 
starting point for MDMA product outlets (MPOs) given that, as a model of 
availability, the pharmacist is uniquely positioned as a gatekeeper for accessibility 
and specialist drug knowledge273, 274. Regulated pharmacy sales make it possible 
for retail to be governed by strict regulatory legislation and a well-defined quality 
assurance infrastructure275. Uruguay was the first country in the world to remove 
the prohibition on cannabis for nonmedical purposes, and is a working example 
of the establishment of this pharmacy model276, 277. With the introduction of this 
model for MDMA products, the government would be able to tightly control 
the MDMA produced. 
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One lesson to be learned from Uruguay’s experience is that the state must 
articulate its commitment to a coherent workable enforcement strategy. A clear 
commitment to enforcing the rules of an emergent state-regulated market for 
MDMA products, such as the establishment of a regulatory agency for MPOs, 
would go some way towards allaying potential public concerns. Finally, drug policy 
reform in Uruguay is aligned with its public health programmes and human rights 
obligations, where prohibition is understood to undermine human rights. As a 
result, the country has been able to respond to criticisms by the International 
Narcotics Control Board, which is the UN’s drug-treaty compliance monitoring 
body278. In reply to condemnation from the International Narcotics Control Board, 
Uruguay has insisted that legalising the recreational use of cannabis is in line with 
human rights obligations which take precedence over international obligations on 
drug control, and that any tension between the two is a matter for international 
debate, rather than blind acceptance of the status quo. Uruguay’s drug policy 
innovations, including its implementation of the pharmacy model, make it one 
of the most progressive drug policy regimes in Latin America, a region all too 
aware of the harms associated with international prohibition. 
Establishing the legal distribution of MDMA in specific outlets requires a 
consideration of the ‘4 Ps’ of marketing: product characteristics, prices charged, 
place where sold, and promotional activity. Aside from the promise of a safer 
product (i.e., no adulterants, consistent dosage, clear labelling, harm reduction 
advice as standard), prices must be competitive if illegal products are to be 
squeezed out of the market279. However, price is but one consideration in drug 
purchasing decisions, with availability and purity (i.e., non-price variables) also 
being part of people’s considerations. MPOs would be conveniently located, 
given that they will, at least initially, be in competition with drug-delivery 
services organised via mobile phones and social media280. However, this in 
no way implies the establishment of a so-called ‘supermarket model’ of drug 
distribution281. MPOs in the pharmacy model would be tightly regulated so 
that no direct or indirect promotional activity takes place either in-store or in 
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other marketing and advertising spaces, such as on social media. In effect this 
would mean a blanket ban on promotional activity. Local pharmacies are ideally 
placed to distribute MDMA, and indeed discussion in the Royal Pharmaceutical 
Society’s professional journal indicates its openness to consider this as part 
of members’ roles282. In relation to MPOs, availability and ease of access are 
important non-price factors to consider, but the concerns of other stakeholders, 
such as local residents, should be addressed, especially given the need to balance 
potentially conflicting priorities, as multi-criteria decision analysis (MCDA) 
is able to do270. The hours during which customers could purchase MDMA 
products from pharmacies/MPOs would, for example, be tightly controlled (as 
the opening hours of NTE venues already are), with more conventional daytime-
only opening hours to control trade and to minimise spontaneous impulse 
purchase, especially if potential customers are already under the influence of 
drugs such as alcohol.
In Chapters 1 and 2 we detailed how MDMA may be but one of a range of 
drugs consumed on nights out or at other leisure times/spaces such as festivals 
or parties in domestic spaces283, with tobacco, alcohol, cannabis, cocaine, and 
ketamine identified as key co-consumed drugs. Having strict regulations to 
reduce the harms of polydrug use must be part of any drug policy reform. As 
such, those serving in MPOs would be bound by the ‘right to refuse purchase’ 
regulation – not serving someone who is judged to be too intoxicated – akin to 
those enacted in on-licence premises such as pubs, bars, nightclubs, and festivalsc. 
Although challenges with ‘right to refuse purchase’ are acknowledged (not least 
because of issues around enforcement), it is imperative that any legally regulated 
market for MDMA ensures the reduction of harm to all stakeholders. Therefore, 
c In the UK for example, under the Licensing Act 2003, it is illegal to knowingly sell alco-
hol, or attempt to sell alcohol, to a person who is drunk. It is also illegal to allow alcohol 
to be sold to someone who is drunk. It is also an offence for a person knowingly to get, 
or try to get, alcohol for a drunken person on licensed premises. Breaking the law could 
result in a fine of up to £1,000. If the convicted person is a personal licence holder, they 
could lose their licence.
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sufficient funds would need to be made available for the enforcement of MPO 
regulation, and to ensure that any MPO licence stipulations are fully adhered 
to. There would be a need, for example, for officially mandated compulsory staff 
training (e.g., of pharmacists in the pharmacy model) concerning MDMA use, 
risks, and harm reduction. Combining detailed staff knowledge and experience 
with age restrictions, quantity limits on purchases, non-branded packaging, and 
labelling requirements providing content and contraindication information 
would further encourage safer MDMA use. ‘Take-away’ educational resources 
would be readily available at these outlets (as well as online) and would include 
information on MDMA-related risks and harms (including combinations with 
alcohol and other drugs), how to identify problematic MDMA use, and up-to-
date information on harm reduction best practices. The successful techniques 
pioneered by contemporary on-site drug safety checking services in engaging 
clients in harm reduction discussions could be translated into future MPOs284, 285.
 
It is worth remembering that many young people are tech-savvy ‘digital 
natives’ who are used to mobile and web-based marketing, and routinely purchase 
goods and services online286. As discussed earlier, there is a growing body of work 
on drug purchasing online, using social media sites and drug cryptomarkets on 
the darknet12, 196, 197, 199, 200. Given this, it is likely that a legally regulated market 
for MDMA may eventually require an online presence, depending on the success, 
or otherwise, of MPOs. This need not involve a purchasing option, but rather 
could consist of a ‘Find My Nearest MPO’ service that also has health and harm 
reduction information prominently availabled. Well-respected harm reduction 
and drug information organisations such as The Loop (UK) have a strong online 
presence, which could be further enhanced in a legal regulatory model.
 
d It is worth noting that precluding any online purchases would exclude people living in ru-
ral areas who may struggle to get to MPOs. That said, the face-to-face contact enabled by 
MPOs in town and city centres remains important for ensuring sensible use conversations 
at point of sale.
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User controls and harm reduction
User controls in MDMA-using contexts would remain crucial in Phase 2 (which 
is laid out in section 3.4 above). User controls would focus on supporting the 
responsible use of a legally manufactured product, rather than on the detection of 
an illegal product, or on mitigating harms produced by consuming an illegal and 
unregulated product. Drug policy reform must have the protection of citizens at 
its heart, and user controls would aim to reduce the use of MDMA by underage 
and vulnerable populations, reduce polydrug use, encourage safer modes and 
patterns of consumption, and improve user understanding of the potential 
harms associated with MDMA consumption. The age limit for MDMA product 
purchase would be 18 years of age. Child-proof and tamper-proof packaging 
of the kind used for medicines and pharmaceuticals would also be required to 
reduce the risk of accidental MDMA poisonings287. 
Pricing and purchase limits
Evidence from alcohol control demonstrates that price can be a powerful tool 
for moderating the consumption of legal drugs288. Price is an example of one 
variable that should come under frequent evidence-based review, to balance 
optimally the need to discourage excessive purchasing against the imperative not 
to push consumers towards more harmful alternatives, particularly illegal market 
MDMA and other available legal and illegal intoxicants. Since typical MDMA 
use is occasional, whilst alcohol can account for a significant proportion of its 
users’ budget, it may transpire that MDMA consumption patterns will not be so 
price-sensitive as they are for alcohol. MDMA is a relatively inexpensive drug 
(as a proportion of disposable income) compared to others, given that typical 
consumption patterns tend towards the infrequent (e.g., occasional, weekend-
only use)289. This means that the incentive to purchase from the legal market as 
opposed to the illegal one will largely depend upon non-price variables such as 
quality, safety, availability, and support and information offered by MPOs. Due 
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to the low cost of producing MDMA, it would be possible to collect a reasonable 
rate of tax on MDMA products whilst still successfully competing with the 
illegal market and allowing legitimate MDMA product vendors potentially 
to cover the costs of the regulatory implementation and required staff training.
 
Limits on the amounts people can purchase at any one time would also 
reinforce the importance of moderating the frequency of MDMA use and the 
quantity consumed. In order to access legal MDMA products, the user would 
have to obtain a ‘personalised licence’. An MDMA product personalised licence 
would only be granted once an adult – on their first visit to an MPO – had 
demonstrated the capacity for safe use by exhibiting sufficient knowledge 
and understanding of MDMA pharmacology, the relative safety of different 
consumption patterns, and the potential harms involved. This capacity would be 
demonstrated during a discussion with an appropriately trained pharmacist. The 
stipulations for a personalised licence would include the monitoring of purchase 
patterns, with challenges made to those attempting to purchase more than a 
reasonable amount for personal use290. If an individual continually purchased (or 
attempted to purchase) more than the recommended limit, they would be subject 
to increased scrutiny from pharmacists and risk losing their personalised licence. 
A ‘reasonable amount’ for personal use would be determined by pharmacologists 
and harm reduction experts. As an active dose of MDMA is 80–100 mg, it 
is likely that this would shape purchase limits alongside personalised harm 
reduction advice. An individual’s level of MDMA experience would, for example, 
be discussed with the pharmacist, and would be noted on the customer’s licence 
for future reference. The personalised licence for purchase of MDMA products 
from MPOs administered by pharmacists would be reviewed on an annual basis.
Marketing controls and information campaigns
Coupled with information on the content and dosage on the packaging, health 
information would be mandated on packaging and at point of sale to highlight 
3 . 4 . 3 . 2
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key risks and discourage use in combination with other drugs or medications. 
In addition, we propose strict marketing controls, specifically a comprehensive 
ban on marketing and advertising, including in-store displays, as these have been 
shown to influence young people’s use of legal drugs (e.g. tobacco) and unhealthy 
food291. Packaging requirements add marginally to costs, as will fees for licensing 
and other quality assurance processes, but these will be borne by the producer/
vendor. Information campaigns around MDMA safety and responsible use are 
central to Phase 2. Such information campaigns would cover all sales outlets 
and educational establishments (schools, colleges, and universities), and would 
include a wide range of health messages, including the risks of polydrug use, 
preventing use during pregnancy, safer dosage information, and information on 
recognising the symptoms of adverse events in relation to MDMA products 
and how to manage them. Additional targeted education programmes would 
address and minimise use by certain groups who are more likely to encounter 
problems, such as young people (under-18s) and individuals with physiological 
(e.g., cardiovascular) or psychiatric vulnerabilities. 
Well-targeted information campaigns would also be deployed to minimise 
the social acceptability of driving under the influence of MDMA, and to 
promote alternatives, such as designated drivers. The success of campaigns to 
reduce the acceptability of driving after drinking would be a useful model. In 
a context where alcohol, MDMA, and cannabis were all regulated, a campaign 
could encourage the generalisation of current norms about the unacceptability of 
drink driving to all driving whilst impaired. In Canada, laws on impaired driving 
are being changed to accommodate the country’s legalisation of the cultivation, 
sale, and consumption of recreational cannabis, with tougher penalties for all 
drug-impaired driving and new roadside tests designed to catch those smoking 
cannabis and driving (within a given time limit)292. However, this call for tougher 
penalties was politically motivated because drug policy change opponents had 
raised ‘driving under the influence’ as one of the many risks of a legal regulation 
model. The Canadian model also suggests that roadside tests are valid ways to 
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establish impairment, when in fact they are not (at least not in the same way as 
alcohol road testing is). The rate of ‘false positives’ (detection of a drug where 
there is none) in existing systems is also worrying293. 
Currently, MDMA is one of a group of eight illegal drugs for which a 
‘zero-tolerance’ approach is in force in the UK regarding drug-impaired driving. 
The law makes it an offence to be in control of a vehicle with any detectable 
trace of these drugs in the bodye, regardless of whether the driver is likely to be 
impaired in any way. This problematic ‘zero tolerance’ approach contrasts with 
the risk-based approach applied to alcohol users, and to the recommendations 
of scientists commissioned by the government to report on the issue294. The 
alternative risk-based approach, as recommended by the aforementioned expert 
panel commissioned by the government294, is for drivers to face prosecution if 
their blood levels of MDMA are above a threshold that research has shown 
to be associated with impairment: 300 µg/L or 150 µg/L if the driver has also 
been drinking alcohol. This risk-based system for defining punishable drug-
driving offences works well for alcohol in combination with strong messages 
discouraging any driving until a person is sober. 
MDMA use in the night-time economy: MDMA-friendly spaces
Night-time leisure spaces are key settings in which MDMA is consumed. As 
most are formally regulated, they provide an environment in which the risks of 
acute MDMA-related harm can be managed and reduced. As well as allowing 
access to a standardised, high-quality, clearly labelled product, Phase 2 should 
allow for the development of adult-only MDMA-friendly spaces where, free 
from the hostility of criminalisation, a culture of responsible usage norms would 
be extended67, 257, 295 and medical assistance would be close at hand. The MDMA-
friendly spaces we propose here could also be ‘dry’. As noted in previous chapters, 
early patterns of MDMA consumption at illegal parties in the late 1980s and 
e Above a threshold deemed to rule out accidental exposure, set at 10 µg/L.
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early 1990s involved ‘dry raves’ where no alcohol was made available to customers 
on-premises (although this is not to say that alcohol was not consumed by party-
goers). Examples of spaces for drug use which already abide by this no-alcohol 
rule include many cannabis cafés in the Netherlands. 
In previous chapters we identified one key feature of contemporary drug use, 
namely polydrug use, including combining MDMA with alcohol. In Phase 2, 
considerable effort would be put into minimising this pattern of consumption 
given its well-documented harms. MDMA makes alcohol users underestimate 
their drunken impairment (and vice versa), and so puts people at higher risk 
of road accidents and similar negative incidents296. Alcohol impairs inhibitory 
control and therefore makes it easier for people who use drugs to consume 
drugs faster or in higher quantities than they may have intended297, a pattern of 
drug use which we also see in relation to the combination of powder cocaine or 
amphetamines and alcohol in the UK’s NTEs.
Currently, some licensed venues are hostile to MDMA use, partly because 
it impacts profitable alcohol sales, and partly due to the ever-present threat of 
licence revocation if a drug incident or drug dealing occurs on their premises. 
This said, most licensed premises ‘perform’ zero tolerance towards all illegal 
drugs298 while knowing that without customers who use MDMA and other 
drugs they would go out of business. At a practical level, it is impossible to 
prevent all drug use in licensed premises. Even the threat of ejection, the threat 
of arrest, a visible security and/or police presence, and stringent searches do not 
deter the many attendees who still smuggle in drugs for their own personal use, 
or that of their peer group. This clandestine environment is far from conducive 
to reducing MDMA-related harms. MDMA-friendly spaces would be non-
clandestine versions of contemporary NTE venues and events. There are already 
some MDMA-friendly spaces in existence, even if they are not explicitly labelled 
as such. These are the licensed venues – typically dance music spaces – where 
owners, staff, and customers understand that the consumption of MDMA is 
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occurring and act responsibly on that understanding. In these spaces, MDMA 
use is neither condoned nor condemned, but rather is acknowledged as a ‘fact 
of life’. Indeed, many harm reduction initiatives – including drug safety testing 
– are premised on this pragmatic acknowledgment of the reality of the enduring 
presence of drug use. Only by bringing MDMA use out in the open, instead of 
it being hidden, can we significantly manage, and reduce, MDMA-related risks. 
What might this look like in practice?
In the UK there are stipulated technical standards relevant to licensed venues 
around the regulation of ambient temperatures and the adjustment of those 
temperatures pertaining to the specificities of the night299. The control of ambient 
temperature and humidity has long been noted as good practice under the 2008 
Safer Nightlife guidelines300, and under specific licensing authorities’ jurisdictions, 
with most recently the City of London stating that temperature levels and 
humidity control is key to public safety in the NTE301. All applications under 
the UK’s Licensing Act 2003 (which came into force in 2005) are accompanied 
by a ‘club operating schedule’ whereby applicants must show how they will 
promote the licensing objectives: the prevention of crime, disorder, and public 
nuisance; the promotion of public safety; and the protection of children from 
harm (which focuses on turning away underage customers). 
However, the Licensing Act 2003 does not include any specific stipulations 
around temperature control302. Further, technical standards and good practice 
measures are not consistently adhered to, nor properly enforced across much of 
the UK. Busier nights in indoor dance venues are often unbearably hot and 
sweaty. This is not acceptable, given the evidence we have laid out in this report 
regarding the risks of dehydration and overheating when on MDMA. Looking 
beyond the UK, the diversity of regulations and the number and range of 
agencies and/or authorities involved, varies greatly across Europe (sometimes 
even within different cities/regions of the same country), as do licensing 
requirements; this makes it difficult to compare legislation and enforcement 
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measures. However, in a 2012 Club Health survey of nightclub industry 
representatives across Europe, a majority (78%) stated that they tried to control 
temperatures at an operational level given its effectiveness at ensuring good 
health and safety inside their premises303. This demonstrates an understanding 
of the problem of overly hot environments alongside a willingness to consider 
the introduction of enforced (rather than voluntary) temperature limits, much 
as noise limiters exist in NTE venues today. 
Throughout this report we have highlighted the importance of the use 
context as it pertains to acute MDMA-related harms. Recommendations for 
drug policy change rest on these details of contextual harm reduction. This 
means that by decriminalising and then legally regulating MDMA, new policy 
possibilities open up, as, in this instance, venues become more responsible for 
the safety of their MDMA-consuming customers, just as they currently are in 
relation to alcohol. In contrast to the prohibitionist status quo, under a state-
regulated legal market, MDMA-friendly venues and events would be required 
to take steps to minimise risk and nurture responsible MDMA use. These may 
include more strictly enforced regulations to ensure that dancefloors and festival 
tents are cool and well ventilated. The employment of doctors at festivals has 
been shown to prevent many drug casualties requiring hospitalisation, reducing 
impacts on local health services304. MDMA-friendly spaces would then be 
Figure 17
Source: Pixabay
Nightlife.
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legally bound to ensure that adequately trained in-house medics are available. 
MDMA-friendly spaces would continue to welcome adult users into regulated 
spaces where under-18s are strictly excluded, as is currently the case in UK 
nightclubs. However, the strict exclusion of under-18s from MDMA-friendly 
spaces may involve the continuation of MDMA use by teenagers in unregulated 
spaces such as parties in domestic spaces and illegal raves245 246, the latter of which 
have grown in number in recent years305. Following legal regulation, teenagers 
may still consume MDMA (although strict age restrictions will apply), but the 
products they consume will be standardised; education and information will be 
considerably improved; and perhaps most crucially, if something goes wrong, 
they will be less fearful of the repercussions around calling for help.
On-site MDMA sales in the night-time economy
Given the association between dance music cultures and MDMA use, it would seem 
at first glance that the establishment of a regulated legal market should necessarily 
incorporate the on-premises purchase of MDMA products at dance music clubs, 
events, or MDMA-friendly spaces. However, the presence of alcohol, the likely 
reticence of venue owners to such a scheme, and the need to ensure that harm 
reduction information is conveyed within an environment conducive to rational, 
informed choice, does not sit well with such a model of MDMA distribution. 
Yet the phased nature of reform in this roadmap to regulation does mean that if 
single-drug use became normalised and polysubstance/polydrug use increasingly de-
normalised, the make-up of the UK’s NTE may change, creating space for increasingly 
‘pharmacologically specialised’ venues or eventsf. Existing dance music brands and 
dance music-oriented venues where customers were already predominantly MDMA 
users may wish to change their business model and move towards the model of 
MDMA-friendly spaces outlined here, replacing alcohol bars with ‘in-house’ MPOs. 
f This may include the ‘pharmacological specialism’ of ‘no alcohol or drugs’ spaces which 
already exist in cosmopolitan urban centres, for example the many shisha bars and gelato 
parlours frequented by teetotal young people.
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3 . 4 . 4Monitoring and evaluation
The implementation of Phase 2 must draw on the evidence base around other 
regulated markets such as tobacco and alcohol to develop assumptions about 
what the hypothesised impact of an MDMA policy change might be. For 
MDMA products, even more than is the case for cannabis (currently the 
most developed emergent regulatory model apart from alcohol, tobacco, and 
prescription medications), there are significant areas of uncertainty. It would 
be important to perform detailed impact assessments based on variations in 
parameters (including levels of price/taxation, and availability) via different outlet 
models. It would also be important to monitor closely changes in outcomes, 
and to have a flexible model that could respond to lessons learned during 
implementation. Monitoring prevalence of use and incidence of specific harms, 
for example, would be crucial to understanding the impact of any MDMA policy 
change. MDMA is a popular recreational drug historically linked to specific 
youth and music cultures in leisure spaces/times. Despite its popularity amongst 
some people, MDMA does not rival alcohol or cannabis in terms of widespread 
use. The aim of the proposed regulatory model is to make this relatively popular 
and comparatively safe drug available to adults within a culture that encourages 
responsible use and harm reduction. Although difficult to forecast, it is possible 
that some increase in the number of users will take place if the drug is available 
legally. Nevertheless, the aim of accompanying controls is to ensure that the 
use is safer, which will lead to a reduction of drug-related harm and associated 
health services costs to the state, as well as maximised benefits. While initially 
the aim would be to control legal access to MDMA products strictly so that the 
prevalence and frequency of use do not markedly increase, certain trade-offs will 
be required, since, if access is made too difficult, the illegal market will continue 
to flourish. If use of legal MDMA is found to cause a net reduction in harms, 
further cautious easing of restrictions might be considered to realise the benefits 
of reducing the use of other potentially riskier drugs, such as alcohol. However, 
at the early stages, a cautious regulatory model is most appropriate. 
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Around the early 1980s, governments across the world had a choice. MDMA, 
an emerging drug with quite unique effects, was growing in popularity. With 
the benefit of hindsight, we can speculate about how they might have chosen to 
implement a regulatory structure to manage the burgeoning market for MDMA, 
and nurture the development of a socially integrated culture of responsible 
recreational MDMA use. Instead, prohibition of the drug was instituted locally 
and globally. The result has been a worst-case scenario, a ‘lose-lose’ situation. 
Those fighting to eliminate MDMA in order to defend public health, have 
proved powerless in preventing it from becoming one of the world’s most 
popular recreational drugs. Therapists hoping to explore MDMA as a tool 
to bring wellbeing to suffering people, have had their ambitions frustrated. 
People wanting the choice to take a managed personal risk in exchange for 
a pleasurable experience can only take an unmanaged gamble with pills and 
powders of sometimes dubious composition, while risking potentially life-
changing criminal sanctions for a consenting adult behaviour, less risky than 
many already legal activities. Public services such as hospitals and courts, and 
ultimately taxpayers, bear all the financial costs associated with its use, whilst 
criminals harvest the rewards. The human costs of entirely preventable deaths 
are impossible to quantify. 
In the bitterly ironic terminology of the MDA 1971, MDMA is a ‘controlled 
drug’. In truth, no control exists over its synthesis and formulation into a 
reliable product, its importation and distribution, or its use. Illegal MDMA is 
uncontrolled by default, yet there is no reason to believe that it is uncontrollable 
within the legal sphere. The Beckley Foundation advocates meaningful drug 
control. What would it mean for MDMA to be a state-controlled, legally 
available drug? Government control through legal regulation would steer 
outcomes in the desired direction. Currently, the government’s lack of control 
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means they are failing to manage outbreaks of toxic adulterants such as PMA, 
or surges in pill/tablet dose. People are dying needlessly in growing numbers as a 
result. The government claims that MDMA is prohibited because it is dangerous, 
but this is not so much a falsehood as a non sequitur. The intrinsic dangers of 
MDMA, relatively moderate as they are, are only compounded by prohibition. 
This report has set out an alternative framework for a system of MDMA control. 
Given that such a move has few, if any, precedents, our framework leaves plenty 
of room for each element to be trialled and adapted in response to evidence 
and to the public will.
Supporters of the ‘tipping point’ model of drug reform argue that prohibition 
has started to crumble, although this claim is contested by those who point to, 
for example, the increasing militarisation of drug law enforcement. However, 
incremental change is afoot in some areas. Until recently, many citizens took it 
on trust that cannabis had to be illegal to prevent a public health catastrophe. 
Now public opinion is shifting, as the spread of legal cannabis in the US – albeit 
under a far from optimal, highly commercialised, lightly regulated regime – 
undermines those myths. A more strictly regulated cannabis market in Uruguay 
demonstrates that there are multiple pathways available, and Canada is now 
carving a path somewhere between the US commercial models and the Uruguay 
state control models, adding more to our understanding of policy options. While 
cannabis proves that prohibition is not the only way to manage recreational 
drugs, the very different nature of MDMA’s effects, risks, and consumption 
practices means we cannot uncritically adopt and apply successful elements of 
cannabis, alcohol, or tobacco regulation without careful consideration of their 
likely consequences in a new context. MDMA regulation is a unique challenge. 
When instituted it will be the first modern regulated market for a stimulant of 
any kind, apart from BZP in New Zealand. However, this is not to suggest that 
MDMA regulation would be a reckless step into uncharted territory. Unlike 
alcohol, tobacco, or caffeine, MDMA is not dependence-forming. We already 
successfully moderate the risks of other substances that are toxic in overdose 
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such as paracetamol, which demonstrates how relatively simple regulations on 
packaging and distribution can reduce rates of harm and death.
It is imperative that evidence guides policy choices. This is of course difficult 
in our local and global political climate, where governments remain reluctant 
to engage meaningfully with debates around drug reform as a highly complex 
(and easily sensationalised) policy arena. As with the psychedelics, the power 
of MDMA to induce extremes of experience and to shock the imagination of 
others can be perceived as more threatening to established social norms than as 
a result of any quantifiable harmful consequences of use. Tobacco, as a regulated 
product, kills one in three of its dedicated users, but generally in a way that fits 
the established cultural template for what death looks like (ill people in beds). 
This combined with the absence of obvious intoxication means tobacco does 
not naturally evoke a comparable degree of social anxiety as MDMA. MDMA-
related deaths typically occur suddenly and shockingly, in nightclubs, at festivals, 
and at parties; these spaces are associated with celebration, not devastation. 
MDMA-related deaths are nearly always covered in the media, typically in 
a sensationalist, even ghoulish manner. However, behind the appearance of 
entrenched division in the drug policy debate, there may be more unity than is 
recognised, in the form of a common desire to minimise harm and keep people 
safe. Right now, on a weekly basis, around two people in the UK will die having 
introduced unregulated MDMA products into their bodies. In response we need 
to build consensus that taking control of MDMA is the route forward. We have 
already lost decades of potential MDMA policy reform, so now is not the time 
to tinker. Without a more fundamental change to our approach to MDMA, 
we risk letting down current and future generations of citizens. Let us not have 
another wasted decade.
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At 11.20 a.m. on the 20th of July 2013, I got the phone call that no parent wants 
to receive. A stranger told me that ‘my 15-year-old daughter was gravely ill and 
they were trying to save her life’. Nothing can prepare you for a moment like 
that and luckily most people will never get to know how this type of loss feels. 
I’ve heard it said that losing a child is the ultimate burglary and for the past six 
years it has felt as though I’m still hoping for my girl to come home. Of course, 
I know she won’t, but it’s as though every cell in my body is programmed to 
being Martha’s mum and they’ve yet to find their new purpose. 
So, my reality is that one minute I was a single mum to a beautiful 15-year-
old daughter who was three months away from her 16th birthday, and the next 
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Anne-Marie Cockburn (Martha’s mum)
    Source: Anne-Marie CockburnFigure 18.      Martha Fernback. 
117
I was childless and alone. A bereaved single mother. Those words choke me as I 
type them – I don’t relate to them because I simply don’t want them to be true.
I always worried that something would happen to me and that Martha 
would be left motherless – but never, ever did it occur to me that she’d go first. 
Seeing your gorgeous child’s photo beneath an horrific headline on the front 
page of all the newspapers is the most hideous, surreal experience. I just couldn’t 
believe it – the adrenaline and diazepam kept me numb for the first few weeks, 
and in time I reluctantly came back down to earth and started to search through 
the wreckage of my old life, in order to find answers to help try to make sense 
of what had happened. But it doesn’t make sense and it never will.
As a parent you do everything you can to help guide your child through 
life – ‘have you got sunscreen on, did you eat your lunch, don’t forget your bike 
helmet’ – and as they get a little bit more freedom you hope that everything 
you’ve taught them up to that moment will be enough to see them home safely 
every day. But lurking in every community is a danger that I was so blissfully 
ignorant of, a danger so widespread that it’s become the biggest black market on 
planet earth, a danger that I naïvely didn’t think related to ‘a family like mine’. 
How wrong I was – how clueless and ignorant. I shake my head at my former 
self and wonder why I had this opinion. Well, I’ve learned the hard way and I’ve 
learned very quickly what I should have known then. 
My precious girl’s life was wiped away within two hours of swallowing half 
a gram of white powder that turned out to be 91% pure MDMA – I’ve been 
told it was enough for 5–10 people. Martha died from an accidental overdose at 
exactly 2.17 p.m. on a beautiful sunny Saturday afternoon. Just like that.
My girl truly loved life, but she was curious as many teenagers are. Martha 
wanted to get high, but she didn’t want to die. No responsible parent wants either, 
but you’d prefer one of those options to the other. That is why I want MDMA 
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to be legally regulated. Plain and simple. Twelve people die every single day in 
the UK from a devastating drug-related death. This means twelve more families 
have to live with the agonising reality that their loved one’s death was preventable.
 
No drug is made safer by leaving it unregulated on the black market. Under 
the current system, whether you’re 5 or 55 you can get easy access to pretty much 
any substance you want – there is no request for ID, there is no enquiry as to 
your health, or concern for your wellbeing. The laws are supposed to keep us safe 
– but the Misuse of Drugs Act 1971 isn’t fit for purpose. Drug prohibition has 
achieved exactly the opposite of what it was set up to do. Therefore, I believe that 
it is time for our government to be more visionary and to look at new approaches 
in order to start to truly control and regulate all drugs, including MDMA.
The difference between a poison and a medicine is the dose. Had Martha 
taken something that was licensed, labelled with a list of ingredients and 
recommended dosage, she’d still be alive today. My vision is for a legal regulatory 
model that is for those aged 18+. Under this model even if a younger person 
inadvertently got their hands on something, at least they could make a more 
informed decision. I don’t want the world to lose another Martha and that is 
why I tirelessly campaign for legal regulation. 
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On the front line of the War on Drugs
Neil Woods
In 2013 Professor David Nutt, former Chair of the UK’s Advisory Council for 
the Misuse of Drugs, publicly declared that the prohibition of certain drugs 
was the ‘worst case of scientific censorship since the Catholic Church banned 
the works of Galileo’306. His point still stands. For decades, scientific research 
into substances which offer us an improved understanding of the human mind 
and which have therapeutic potential have been curtailed by global anti-drug 
laws. However, this scientific censorship is increasingly being questioned, most 
recently with the Advisory Council for the Misuse of Drugs’ recommendation 
that regulated cannabis-based medicines be made available in the UK, following 
a public campaign by parents of children whose epilepsy is better managed by 
such medicines. Whilst it is difficult to get a licence to research drugs such as 
cannabis and MDMA, and their illegality makes them prohibitively expensive, 
scientific studies examining their potentially therapeutic properties have been 
undertaken, including on the therapeutic potential of psilocybin and ketamine 
to treat severe depression, and more recently, the success of trials of the treatment 
of post-traumatic stress disorder (PTSD) using MDMA. 
The work of the Multidisciplinary Association for Psychedelic Studies 
(MAPS) based in the US is hugely exciting. As a sufferer of PTSD, I have a 
personal interest in this. I live with an increasing number of debilitating PTSD 
symptoms, of which the most persistent and tiring is a profound sense of guilt. 
I have moments where I exist completely in a memory from over a decade 
ago, and in so doing I develop breathtaking anxiety. I worry that I will never 
escape from the memories, all of which concern people I have harmed. As an 
undercover police officer, I was tasked to catch gangsters. I used and manipulated 
vulnerable people in order for them to introduce me into the ranks of organised 
crime. During many years of this shady work I had numerous near-death 
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experiences. I’ve had a samurai sword held to my neck and a knife to my groin. 
I’ve been stripped at gunpoint and been the target of a deliberate hit-and-run 
attempt, from which I narrowly escaped. These events have contributed to my 
current mental state. However, the most dominant memories are of the people I 
endangered with my Machiavellian manipulations. Anyone introducing a police 
officer to the gang is likely to suffer, but I made the decision to involve others 
time and time again, despite being fully cognisant of the dangers they would 
be exposed to. There is no other form of policing for which the end justifies 
the means: whereby inflicting harm on somebody is warranted in order to get 
a desired result. The War on Drugs has brought a military mindset to policing, 
and with it has come a condition associated with military action.
As a society we now have a better awareness of PTSD. It is widely understood 
that trauma of all sorts can leave considerable mental scars. We have come a long 
way from soldiers suffering from ‘shell shock’ being considered cowards. Complex 
PTSD is a condition which is not caused by a single event. A car crash survivor 
may suffer PTSD symptoms from one occasion, but for sufferers like me, things 
cannot be clearly traced to a specific moment in time. I have colleagues in Law 
Enforcement Action Partnership (LEAP) UK with similar symptoms to me. We 
have all done other police work and been at risk during conventional policing, but 
our symptoms relate specifically to our undercover drugs work. The trials by MAPS 
have had former soldiers take part, but there is also a police officer who benefited 
from the experiments. I have discussed the trials with my colleagues in LEAP 
US and there is a growing understanding amongst law enforcement professionals 
of the close relationship between the War on Drugs and PTSD. The possibility 
of a new treatment is welcomed amongst those that acknowledge the problems 
associated with the condition. I spoke, for example, with retired Detective Justin 
Boardman, of the West Valley City Police Department, Utah, who told me:
MDMA therapy shows promise to be a key component in holistic mental 
health treatment for the police. We don’t have enough options, and we’re 
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often punished for being open about our trauma. Good officers lose their 
jobs for seeking help. Better departmental policy and access to treatment, 
including MDMA therapy, could help keep our best officers on the street.
This is a startling thing to hear from a police officer in the US – a nation at 
the heart of the War on Drugs. Perhaps, as it becomes more widely acknowledged 
that PTSD is a symptom of that war, the dark irony of this situation will become 
clear to everyone: the possibility that one of the drugs suppressed by prohibition 
could be key to relieving the stress and damage caused by it. 
The claims of censorship made by Professor David Nutt were met with a 
variety of reactions in the media and scientific community. At LEAP we are 
police. We are investigators. We follow evidence. In declaring that we should 
follow an evidence-based drug policy, we commit to supporting those in the 
scientific community who share the same goal. This is important, for how can 
we follow evidence if scientific research is suppressed? The work of MAPS 
on PTSD in relation to MDMA will, I believe, be one of the most important 
steps on the road to recovery from prohibition. Not only does it cut through 
the ideological propaganda relating to the use of the drug, it also offers new 
understanding of the harms caused by the misinformation which so often stems 
from the War on Drugs.
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MDMA-assisted psychotherapy as a 
potential treatment for alcoholism
Dr Ben Sessa
MDMA has been studied successfully in the last 30 years as a treatment for 
PTSD. The MDMA non-ordinary state of consciousness allows the user to 
safely address painful emotional memories that would normally be avoided. 
Often patients with PTSD have had early childhood traumatic experiences. 
My experience as a child and adolescent psychiatrist working with abused and 
maltreated children has shown me how unresolved childhood trauma frequently 
develops into adult disorders, particularly addictions. In recent years, my work 
with adult patients with addiction has shown the huge difficulty in treating 
alcoholism because patients often cannot address and resolve their childhood 
issues. As a result, modern psychiatry’s success rate at treating alcoholism is very 
poor, not much better than in Victorian times: 90% of patients will return to 
drinking within four years after detox and the best available treatment.
This led our team in Bristol to develop a study exploring MDMA-assisted 
psychotherapy as a treatment for alcoholism. While classic psychedelic drug-
assisted psychotherapy (e.g., with LSD and psilocybin) has a rich history in the 
treatment of addiction, ours is the world’s first study to explore MDMA-assisted 
therapy for the treatment of any addiction. The rationale is that, since trauma so 
often underlies addiction and MDMA appears to be effective at treating trauma, 
MDMA therapy could be useful for treating alcoholism. 
We are currently running a small, open-label proof-of-concept feasibility 
study to prove the safety and tolerability of MDMA-assisted psychotherapy in 
Bristol. The project is affiliated with Bristol University and Imperial College, 
London, who are sponsoring the study. Our aim was to treat twenty patients 
with a diagnosis of alcohol use disorder using an eight-week course of MDMA-
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assisted psychotherapy, which entails taking MDMA twice during the course of 
the eight-week therapy, spaced between non-drug preparation and integration 
therapy sessions.
Myself and co-therapist Dr Laurie Higbed, an addiction clinical psychologist, 
are carrying out the psychotherapy sessions. The main outcome measures are the 
safety and tolerability of this form of drug-assisted psychotherapy for patients 
with alcohol use disorder. All patients are screened according to strict inclusion 
and exclusion criteria for eligibility. We monitor physiological observations 
throughout the MDMA sessions and for seven days after each MDMA session. 
We see them for eight weeks during the therapeutic course, and then for nine 
months of follow-up after the therapeutic course to collect outcome data. We 
assess drinking behaviour and other measures include participants’ mental health, 
physical health, quality of life, sleep, and suicidal status.
So far, we have fifteen patients fully enrolled and we have carried out twenty-six 
MDMA-assisted psychotherapy sessions. Results are promising, with participants 
reporting MDMA effects of profound significance. It appears MDMA-assisted 
psychotherapy helps to unlock rigid, maladaptive, addictive behaviours and support 
a move towards recovery. There have been no serious adverse events and patients 
report finding the course to be safe and tolerable, far superior to previous attempts 
at tackling their lifelong alcoholism. So far, of the thirteen patients who have 
completed the therapeutic course, only two have returned to their full levels of 
drinking that they presented with at the start of the course. The project aims to run 
until December 2019. Thereafter, the Bristol-Imperial MDMA-for-Alcoholism 
team hope to progress to a placebo-controlled randomised study.
Due to MDMA’s status as a Schedule 1 drug, we have encountered enormous 
financial and regulatory hurdles in setting up this project. The costs of obtaining 
Schedule 1 licences at multiple sites and overcoming regulatory hurdles associated 
with obtaining clinical-grade MDMA have impacted our progress. The current 
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scheduling of MDMA under the Misuse of Drugs Regulations is significantly 
impairing its clinical research. In total, including manufacturing costs, approval 
certificates, transport, storage, encapsulation, pharmacy, and dispensing costs, our 
MDMA is costing the study approximately £9,000 per gram. This prohibitive 
cost, due primarily to its Schedule 1 status, puts off many would-be researchers 
and seriously hampers advances in this vital field of medical research, which 
could have enormous benefits for a large population of patients for whom current 
traditional clinical treatments are sadly often ineffective.
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